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Abstract  
Background  
Fibromyalgia (FM) is a multifactorial condition of unknown aetiology. Although it is 
primarily characterised by chronic diffuse pain, it is also associated with a number of 
symptoms including: cognitive impairment, sleep problems, fatigue, anxiety and 
depression. FM patients frequently report of a reduced quality of life, and this often 
due to the inherent disability associated with these symptoms. Although there is 
currently no curative treatment for FM, the anti-convulsant drug pregabalin is one of 
a number of interventions employed to manage this condition.  
Objectives  
To assess the efficacy and tolerability of pregabalin for the management of FM in 
adults compared to a placebo. 	 
Search methods  
Electronic searches were performed using the Cochrane Central Register of  
Controlled Trials (CENTRAL) (Issue 1, 2017), MEDLINE accessed through PubMed  
(1966 to December 2016), and www.clinicaltrials.gov (website of the US National 
Institute of Health) to December 2016 for unpublished clinical trials. Additionally, 
searches were performed on the bibliographies of existing reviews to retrieve 
relevant articles.   
Selection criteria  
The studies included in this review investigated the efficacy and tolerability of 
pregabalin for the management of FM in adults. They were all full journal 
publications of randomised controlled trials (RCTs) which employed a double-blind 
experimental procedure and lasted for eight weeks or longer.  
 
Data collection and analysis  
The titles and abstracts of studies were individually scrutinised to determine their 
eligibility for inclusion. Studies which obviously did not satisfy the basic inclusion 
criteria (i.e. double-blind, RCT) were excluded outright. Full copies of potential 
studies were obtained and read in-depth to ascertain their eligibility for inclusion.  
The risk of bias was determined for each study using the criteria described in the  
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Cochrane Handbook for Systematic Reviews of Interventions [Higgins and Green  
2011]. Data was then extracted and double-checked for accuracy prior to entry into  
Review Manager 5 [RevMan, 2014]   
Main results  
This review includes eight studies of both classical and enriched enrolment 
randomised withdrawal (EERW) design.   Six studies of classical design (3812 
participants) were included in this review.  Participants were randomised at the start 
of the study to receive either: 150, 300, 450 or 600 mg daily pregabalin or placebo 
for 8 to 13 weeks. All studies used a placebo as the comparator. The studies had a 
low risk of bias with the exception of the last observation carried forward (LOCF) 
imputation for missing data which can overestimate or underestimate the magnitude 
of treatment effect.  With regards to pain outcomes, pregabalin was more effective 
than placebo in reducing mean pain scores (SMD: -0.26; 95% CI; -0.34 to -0.19; P = 
<0.00001), as well as achieving both ≥30% (RR: 1.38; 95% CI; 1.23 to 1.55; P = 
0.00001) and ≥50% reductions in pain intensity (RR: 1.61; 95% CI; 1.35 to 1.93; P = 
0.00001); the numbers needed to treat for an additional beneficial (NNTB) outcome 
by pregabalin over placebo was ≈9 and ≈12 respectively. The overall effect of 
pregabalin in producing improvements to patient global impression of change (PGIC) 
was statistically significant (RR: 1.40; 95% CI; 1.25 to 1.58; P = 0.00001); the NNTB 
by pregabalin over placebo was ≈9. Pregabalin did not substantially reduce fatigue 
(SMD: -0.17; 95% CI; -0.25 to -0.09; P = <0.0001), anxiety (SMD: -0.13; 95% CI; -
0.21 to -0.06; P = <0.0007), depression (SMD: -0.10; 95% CI; -0.18 to -0.02; P=0.01) 
or health related quality of life (SMD: 0.17; 95% CI; -0.26 to -0.09; P = <0.0001), but 
produced modest improvements to symptoms of sleep problems (SMD: -0.34; 95% 
CI; -0.42 to -0.27; P = <0.0001). The incidence of participant withdrawal was higher 
with pregabalin than placebo (RR: 1.75; 95% CI; 1.42 to 2.15; P = 0.00001); the 
numbers needed for an additional harmful outcome (NNTH) by pregabalin over 
placebo was ≈12.  Somnolence and dizziness are two of the most common side-
effect of pregabalin; both occurred more frequently following treatment with 
pregabalin as opposed to placebo; (RR: 3.89; 95% CI; 3.16 to 4.78; P = 0.00001) for 
dizziness and (RR: 3.42; 95% CI; 2.71 to 4.32; P = 0.00001) for somnolence. The 
NNTH by pregabalin over placebo was ≈3 for dizziness, and ≈7 for somnolence 
respectively.  With regards to the incidence of serious adverse effects, there was no 
significant difference between pregabalin and placebo (RR: 1.06; 95% CI; 0.73 to 
1.53; P = 0.31). Two studies (687 participants) of EERW design were included in this 
review. They were deemed as having a low risk of bias as there was no missing data 
and no imputation. The maintenance of therapeutic effect (MTR) was used as the 
primary efficacy outcome in this review. Of the participants whom entered the 
double-blind treatment phase, 39.8% of participants receiving pregabalin, and 20.9% 
of participants receiving placebo achieved MTR. The overall effect of pregabalin on 
achieving MTR was statistically significant (RR: 1.9; 95% CI; 1.5 to 2.4; P = 0.00001) 
and the NNTB by pregabalin over placebo was ≈5. As with the studies of classical 
design, the incidence of adverse effects was higher with pregabalin than placebo. 
64.9% of participants experienced at least one adverse effect following treatment 
with pregabalin, as opposed to 48.7% of those receiving placebo. The overall effect 
of pregabalin in causing adverse effects was statistically significant (RR: 1.3; 95% 
CI; 1.2 to 1.5; P = 0.000028), and the NNTH by pregabalin over placebo was ≈6.   
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Author’s conclusions  
Pregabalin 300 to 600 mg daily has the potential to achieve substantial 
improvements the symptoms of FM, but this is generally observed in a minority of 
participants. Although its use can yield small improvements to the symptoms of pain 
and sleep problems, it is generally less effective in addressing the other symptoms of 
FM (i.e. fatigue, anxiety). Although the use of pregabalin is not associated with any 
serious adverse effects, participants typically experience adverse effects (i.e. 
somnolence and dizziness) more frequently than in the placebo group.  Furthermore, 
the incidence of participant withdrawal due to adverse effects was higher in the 
pregabalin group. Generally speaking these observations did not follow a dose 
response relationship.   
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Plain language summary  
Pregabalin versus placebo for the management of fibromyalgia in adults  
Fibromyalgia (FM) is typically characterised by chronic diffuse pain, but is also 
associated with a number of symptoms including cognitive impairment, fatigue, sleep 
problems, anxiety and depression.  There is currently no curative treatment for FM, 
and over-the-counter medication(s) are generally ineffective for the management of 
these symptoms. As a result, FM patients frequently report of a reduced quality of 
life; novel treatment options are therefore of growing interest to clinicians and 
patients alike.   
Pregabalin is an anti-convulsant (anti-epileptic) drug which is used for the 
management of FM in certain parts of the world. Its use has been associated with 
marked reductions in pain intensity, as well as significant improvements to the 
associated symptoms of FM. However, it is not currently licenced for the treatment of 
FM in the United Kingdom (UK).   
This review aimed to evaluate the efficacy and tolerability of pregabalin for the 
management of FM in adults, utilising evidence which was considered robust, and 
outcomes which were deemed clinically significant. Our results showed that 
pregabalin has the potential to substantially reduce pain intensity, as well as achieve 
significant improvements to sleep quality and the patients‟ quality of life. It was 
generally less effective in managing symptoms of anxiety, depression and fatigue. 
Common side effects of pregabalin include somnolence (inability to sleep) and 
dizziness, although its use is generally not associated with any serious side effects.   
Background  
Description of the condition  
Fibromyalgia (FM) is a multifactorial condition characterised by chronic diffuse 
musculoskeletal pain, as well as a constellation of symptoms which can include:  
fatigue, sleep-disturbances, depression and varying degrees of cognitive impairment 
[Clauw, 2014; Rahman et al, 2014]. Patients frequently report of a reduced quality of 
life, and this is often due to the inherent disability [Bennett et al, 2007], loss of 
independence, and extensive use of medical care [Häuser et al, 2015] that is 
associated with the condition.   
  
The definitive aetiology and pathogenesis of FM remains unknown, although there 
appears to be a significant degree of variation in its cause and consequence [Clauw 
et al, 2014] [Rahman et al, 2014]. Due to this in part, the classification of FM is 
debated, with some rheumatologists considering it to be a specific pain disorder or 
pain sensitivity syndrome [Clauw, 2014; Yunus, 2008], whereas others coin it a 
functional somatic syndrome or somatoform disorder [Hauser and Henningsen, 
2014].   
  
As described by Sommer et al. [2012], the factors which may predispose, trigger or 
exacerbate the symptoms of FM are varied, and can include: depression, 
psychosocial stress (i.e. work and family conflicts), physical stress (i.e. infection, 
surgery, accidents), genetics, physical and/or sexual abuse experienced in 
childhood, sleep problems, and other lifestyle choices such as smoking or physical 
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inactivity (as reviewed by Bellato et al, 2012]). To complicate matters further, 
comorbidities such as depression and post-traumatic stress disorder (PTSD) are 
known to worsen symptoms [Lange and Petermann, 2010; Wolfe et al, 2013], 
suggesting that the condition may perpetuate as a vicious cycle in the absence of 
appropriate intervention.  
 
Pathophysiological changes which may underlie the development of FM have been 
described, although their roles in this process are considered speculative [Clauw et 
al, 2014; Rahman et al, 2014; Sommer et al, 2012].  For example, following the 
observation that the concentrations of neuroendocrine transmitters (i.e. serotonin, 
cortisol, substance P and growth hormone) were altered in patients with FM, it was 
postulated that the dysregulation of the autonomic and/or neuroendocrine system 
may underlie the pathogenesis of FM [Jahan et al, 2012]. Other possible 
explanations include alterations to sensory processing in the brain (i.e. due to central 
sensitisation) [Woolf, 2011], attenuated reactivity of the hypothalamus-pituitary 
adrenal axis [Ross et al, 2010], and alterations to the balance of anti-inflammatory: 
pro-inflammatory cytokines [Wallace et al, 2014].   
  
At present, there is no diagnostic test for FM. Although routine laboratory 
investigations may be considered to support in diagnosis, they are generally avoided 
unless there is sufficient cause to do so (i.e. swollen joints and suspected 
rheumatoid arthritis). Instead, a differential diagnosis is established by the individual 
assessment of a patient’s symptoms [Wolfe et al, 2011] using the criteria set by the 
American College of Rheumatology (ACR) [Wolfe et al, 2010]. This typically involves 
a discussion between patient and doctor regarding symptoms and their severity, 
which is then recorded and translated into a score to ascertain the degree of 
„fibromyalgia-ness‟ [Wolfe et al, 2010]. Prior to this, the ACR (1990) classification 
criteria was used, which defined FM as “widespread pain lasting for longer than three 
months” with “mild or greater” tenderness observed following palpitation at 11 or 
more of the 18 specified „tender points‟ (i.e. the sub-occipital muscle insertions) 
[Wolfe et al, 1990]. The reasons for this change included the fact that clinicians 
rarely (or inaccurately) performed tender point examination, and there was no 
comprehensive assessment of symptoms other than pain [Wolfe et al, 2010]. 
Although a physical examination is no longer required, it is still recommended to 
identify other possible causes for the patient’s symptoms.  
  
It is not uncommon for multiple diagnoses to be made to capture the full spectrum of 
symptoms. This is due to the considerable overlap between the symptoms of FM and 
other conditions such as neuropathic pain (20-35% overlap) [Koroschetz et al, 2011]. 
Subsequently, the ACR (1990) and (2010) diagnostic criteria are often employed in 
conjunction [Wolfe et al, 1990; 2010].   
Today the prevalence of FM is estimated at approximately 2-3% of the general 
population [Branco et al, 2010; Wolfe et al, 2013], although this may vary between 
geographic populations [Queiroz et al, 2013] and is likely be higher due to 
misdiagnosis or under-diagnosis [Wolfe et al, 2013]. FM has typically been 
considered a female dominated condition, but following the introduction of the ACR 
(2010) classification criteria the proportion of female to male sufferers was estimated 
to have changed from ≈8:1 to ≈2:1 [Derry et al, 2016]. It is thought that this was a 
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result of men having fewer „tender points‟ than women do [Leresche et al, 2011], 
meaning they were often underdiagnosed using the ACR (1990) tender-point 
examination. This new value is more consistent with other chronic pain conditions 
[Vincent et al, 2013] and thought to be a better representation of FM sufferers in the 
present day.  
Generally speaking the management of FM requires a multi-disciplinary approach, 
with pharmacological interventions being combined with physical and/or cognitive 
therapy [Okifuji and Hare, 2013]. As there is no universally effective treatment for all 
FM patients, a multi-pronged approach is employed to manage patients on an 
individual basis. Pharmacological interventions include: conventional analgesics, 
anti-depressants (i.e. serotonin-noradrenaline reuptake inhibitors) [Lunn et al, 2014; 
Wolfe et al, 2013], tricyclic agents (i.e. amitriptyline) [Moore et al, 2015] and 
anticonvulsants like pregabalin [Derry et al, 2016; Okifuji and Hare, 2013].   
Description of the intervention  
Pregabalin is a successor to gabapentin and was introduced as an anti-convulsive 
agent for patients with epilepsy in 2004. In the United Kingdom (UK), pregabalin is 
approved for the treatment of peripheral and central neuropathic pain, epilepsy and 
generalised anxiety disorder; however, it is not currently licensed for the treatment of 
FM. Pregabalin was first licenced for the treatment of FM in 2007, and is currently used 
in the USA, Canada, and a number of countries in South America, the Middle East, 
and Asia. Guidance from the National Institute for Health and Care Excellence (NICE) 
suggests that treatment with pregabalin should be initiated at a relatively low dose of 
150 mg daily. This is generally split into 2-3 divided doses and may be increased after 
3-7 days to 300mg daily, or to a maximum of 600mg daily after a further 7 days. 
Generally speaking this depends on the individual’s response and tolerability to 
pregabalin, and is left to the discretion of the patient-practitioner.  
 
How the intervention might work  
Pregabalin is broadly defined as a gamma-aminobutyric acid (GABA)-analogue, but 
its mechanism of action is not thought to involve direct interaction with the 
GABAreceptor [Bhusal et al, 2016; Taylor et al, 2007]. This is because pregabalin 
was shown to be pharmacologically inactive at GABA radio-ligand binding sites; and 
the observation that the action of pregabalin was not diminished following co-
administration with GABA-receptor antagonists/agonists [Taylor et al, 2007].   
  
The accepted model explaining pregabalins' mechanism of action is thought to 
involve two different and possibly inter-dependent pathways: - the interaction with 
presynaptic voltage-gated calcium ion channels, and the subsequent activation of 
postsynaptic N-methyl-D-aspartate (NMDA) receptors [Bhusal et al, 2016].  
Pregabalin binds with high affinity to the α-2-δ subunits of the type 1 voltage-gated 
calcium channels found on the presynaptic neurones to induce an allosteric change 
between the calcium channel and proteins of the synaptic vesicle (i.e. syntaxin). 
Ultimately, this reduces the ability of vesicles to fuse and release neurotransmitters  
(i.e. glutamate, noradrenaline and substance P) into the synaptic cleft [Bhusal et al, 
2016; Taylor et al, 2007], conferring the anti-epileptic, analgesic and anxiolytic 
effects of pregabalin [Bhusal et al, 2016].   
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Why is it important to do this review?  
FM is foremost characterised by chronic diffuse pain. At present, the proportion of 
patients with chronic pain who achieve significant pain relief following treatment is only 
estimated at ≈30-50% [Moore et al, 2013]; this value is likely to be even lower for 
patients with FM [Wiffen et al, 2013]. That being said, patients who do achieve 
significant pain relief can experience substantial improvements to their quality of life, 
as well as marked improvements to comorbid symptoms such as fatigue. [Moore et al, 
2010].   
This review aimed to collate reliable and robust evidence regarding the efficacy and 
tolerability of pregabalin for the management of FM. Unlike other reviews, this paper 
aimed to investigate the scope of the condition by analysing the effects of pregabalin 
on multiple symptoms using outcomes which were deemed clinically significant. 
Ultimately, the aim was to develop a greater understanding regarding the utility of 
pregabalin as a standalone treatment for the management of FM in adults.        
Objectives  
To assess the efficacy and tolerability of pregabalin for the management of FM in 
adults compared to placebo.   
  
Methods  
Criteria for considering studies for this review include: 
Types of studies  
The studies included in this review were full journal publications of randomised 
controlled trials (RCTs) which employed a double-blind experimental procedure and 
lasted for eight weeks or longer. All studies obtained written consent in accordance 
with the Declaration of Helsinki. Furthermore, trials were required to have at least 20 
participants per treatment arm because of the growing evidence of bias in small 
studies [Dechartres et al, 2013].  
Types of participants  
Studies included adult participants aged 18 years and above, male or female (neither 
pregnant nor lactating), with a clinical diagnosis of FM using either the ACR (1990) 
or (2010) classification criteria [Wolfe et al, 1990] [Wolfe et al, 2010]. Participants 
were also required to have pain scores of ≥40 mm on the 100-mm visual analogue 
scale (VAS) following the cessation of any relevant pain or sleep medication(s), as 
well as a mean pain score of ≥4 (as recorded daily in a pain diary in the week prior to 
randomisation).   
Exclusion criteria included: the evidence of inflammatory or rheumatic diseases other 
than FM, active infections or malignancies, severe depression, untreated endocrine 
disorders, concurrent neuropathic disorders; as well as any other condition(s) which 
may have compromised the reliability of this investigation. Participants who had 
taken pregabalin in the past and had been non-responsive to treatment were also 
excluded.  
 
Types of interventions  
The studies included in this review investigated the efficacy and tolerability of 
pregabalin, administered at any dose, by any route, for the management of FM 
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compared to a placebo. With the exception of aspirin (≤325 mg/day) and	
paracetamol (≤4 g/day), the use of anti-convulsants (other than pregabalin), 
antidepressants and other medications for pain and insomnia were prohibited.   
The use of non-pharmacologic interventions (i.e. physical therapy) was permitted.  
  
Types of outcome measures  
The outcome measures for this review related to the efficacy and tolerability of 
pregabalin for the management of FM. They were derived in part from the Initiative 
on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) 
[Dworkin et al, 2008], as well as the Outcomes Measures in Rheumatology 
(OMERACT) Fibromyalgia Working Group [Mease et al, 2009] and the best practice 
in the reporting of systematic reviews in chronic pain [Moore et al, 2010b].   
„Key symptom domains‟ defined by FM sufferers and experts [Dworkin et al, 2008; 
Mease et al, 2009] were used to inform of the most clinically significant outcomes for 
use in this review. For example, as most patient’s view of a successful outcome for 
chronic pain involved at least a 50% reduction in pain intensity [O'Brien et al, 2010] 
[Moore et al, 2013], this was deemed clinically significant and included as a primary 
outcome.   
 
As FM is associated with a multitude of symptoms, the efficacy of pregabalin was 
also measured by its ability to address a number of other clinically significant 
outcomes, including improvements to self-reported fatigue, sleep problems, 
symptoms of anxiety and depression, as well as health-related quality of life.   
  
The safety and tolerability of pregabalin was defined by the incidence of (serious) 
adverse effects, and participant withdrawal as a consequence. Additionally, the 
incidence of self-reported dizziness and somnolence were used to support this 
outcome as they are the two most frequent adverse effects of pregabalin [Toth et al, 
2014].  
 
Primary outcomes  
1. Reduction in mean pain score   
2. Participant-reported pain reduction of 50% or greater   
3. PGIC „much or very much improved‟   
4. Self-reported fatigue (MAF-score)  
5. Self-reported sleep problems (MOS-sleep scale)  
6. Self-reported quality of life (SF-36)  
7. Self-reported anxiety and depression (HADS-score)  
  
Secondary outcomes  
1. Participant-reported pain reduction of 30% or greater   
2. Participant-withdrawals due to adverse events   
3. Participants experiencing any serious adverse event (i.e. any adverse event 
or effect that, at any dose, results in death, is life-threatening, requires 
hospitalisation, results in persistent or significant disability/incapacity, is a 
congenital anomaly or birth defect, is an „important medical event‟ that may 
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jeopardise the patient, or may require intervention to circumvent the 
aforementioned characteristics or consequences).   
4. Participants experiencing any specific adverse events, namely dizziness and 
somnolence   
  
Search methods for identification of studies: 
Electronic searches  
Electronic searches were performed using the Cochrane Central Register of  
Controlled Trials (CENTRAL) (Issue 1, 2017), MEDLINE accessed through PubMed 
(1966 to December 2016) and www.clinicaltrials.gov (website of the US National 
Institute of Health) to December 2016 for unpublished clinical trials.   
  
Searching other resources  
Searches were performed on the bibliographies of existing reviews to retrieve 
relevant articles (i.e. RCTs).   
Data collection and analysis  
Selection of studies  
The titles and abstracts of potential studies were scrutinised to determine their 
eligibility for inclusion. Those which obviously did not satisfy the basic inclusion 
criteria (i.e. double-blind, RCT) were excluded outright. Full copies of potential 
studies were obtained and read in-depth to ascertain their eligibility for inclusion.  
Included is a Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) flow chart (figure 1).   
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Figure 1: Study flow diagram  
  
  
Data extraction and management  
Data was extracted and double-checked for accuracy prior to entry into Review 
Manager 5 [RevMan, 2014].  
 
Assessment of risk of bias in included studies  
The Oxford Quality Score was employed as the basis for inclusion [Jadad et al, 
1996], meaning studies had to be randomised and double-blind as a bare minimum. 
The risk of bias for each study was determined using the criteria described in the 
Cochrane Handbook for Systematic Reviews of Interventions. 
1. Random sequence generation (selection bias): Selection bias was deemed as 
being either a „low‟ or „unclear risk‟ depending on whether or not the methods 
used to generate random allocation sequences (i.e. computer random number 
generator) was described. Non-randomised processes were deemed as 
having a high risk of selection bias and were not included in this review.  
   
2. Allocation concealment (selection bias): Depending on whether the method 
used to conceal allocation sequences to interventions was described in 
sufficient detail (i.e. telephone randomisation), studies were deemed as being 
either „low risk‟ or „unclear risk‟ respectively. Studies which did not conceal 
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allocation sequences to interventions were deemed as having a high risk of 
selection bias and were not included in this review.   
  
3. Blinding of participants and personnel (performance bias): Performance bias 
was deemed as being „low risk‟ if the measures used to blind participants and 
personnel from knowing which intervention a participant had received was 
described (i.e. use of identical tablets, matched in appearance and smell). 
Studies which state to be blinded but did not describe such measures were 
deemed as having an „unclear risk‟ of performance bias. Studies which were 
not double-blinded were excluded from this review.   
  
4. Blinding of outcome assessments (detection bias): Studies were deemed as 
having a low risk of detection bias if the measures used to blind outcome 
assessors from which intervention a participant received was described. 
Studies which state to be blinded, but did not describe such measures were 
deemed as having an „unclear risk‟ of detection bias. Studies which were not 
double-blinded were excluded from this review.   
  
5. Incomplete outcome data (attrition bias): Studies were deemed as having a 
low risk of attrition bias if the measures used to deal with incomplete data 
were described (i.e. baseline-observation carried forward), or less than 10% 
of participants did not complete the study. Alternatively, studies were labelled 
as having an „unclear risk‟ of attrition bias if last observation carried forward 
(LOCF) imputation was used. This is due to the fact that LOCF imputation has 
the potential to over-estimate or underestimate the magnitude of treatment 
effect.  
  
6. Selective outcome reporting (reporting bias): Studies were deemed as having 
a „low risk‟ of reporting bias if all relevant outcomes had been reported. If this 
was not the case, reporting bias was stated as being „high risk‟.   
  
7. Other sources of bias: Due to the growing evidence of the risk of bias in small 
studies [Dechartres et al, 2013], those with less than 199 participants, or less 
than 50 participants per treatment arm were deemed as having either an  
„unclear risk‟ of bias or „high risk‟ of bias respectively.   
  
Measures of treatment effect  
For dichotomous outcomes the measure of treatment effect was determined by the 
relative risk ratio (RR). Additionally, the numbers needed to treat for an additional 
beneficial (NNTB) or harmful (NNTH) outcome was calculated for statistically 
significant results using guidance from [Cook and Sackett, 1995].   
 
For continuous outcomes, the standardised mean difference (SMD) was calculated. 
This is because different assessment measures were employed between studies 
(i.e. psychometric scales for depression), and the SMD can standardise the results 
to a uniform scale.  The magnitude of effect size was ascertained using Cohen’s 
categories whereby small effects: SMD =0.2; medium effects: SMD = 0.5; and large 
effects: SMD = 0.8 [Cohen, 2013]. The expanded descriptors for effect size 
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described by [Sawilkowsky, 2009] (i.e. SMD = <0.2 = very small) were also 
employed in this review.    
Uncertainty was expressed using 95% confidence intervals (CIs) using a random 
model.   
  
Unit of analysis issues  
When multiple doses of pregabalin were being compared to a single placebo group, 
the number of participants in the placebo group was split between the different doses 
of the pregabalin group.   
 
Dealing with missing data  
An intention-to-treat (ITT) analysis was performed for participants who did not 
comply with the treatment protocol. However, this was only possible for participants 
who had been randomised and taken at least one dose of pregabalin to provide a 
post-baseline assessment; they were otherwise assigned zero improvement.   
  
Unless otherwise stated, standard deviation (SD) was extracted from existing meta 
analyses or calculated from t-values, confidence intervals or standard errors.  
 
Assessment of heterogeneity  
Statistical heterogeneity was assessed using the I2 statistic, which describes “the 
percentage of total variation across studies that is due to heterogeneity rather than 
chance” [Higgins et al, 2003].  An I2 value of ≥25% indicates low heterogeneity; 
2550% indicates moderate heterogeneity; and ≥50% indicates significant 
heterogeneity [Higgins et al, 2003].  
  
Assessment of reporting biases  
Reporting bias was assessed by inspection, ensuring there were no discrepancies 
between the results of quantitative analyses and the purported outcomes stated in 
the methods section.  
  
Data synthesis  
Each meta-analysis was performed using a random effects model in RevMan5 
[RevMan, 2014].   
  
Subgroup analysis and investigation of heterogeneity   
Subgroup comparisons were performed for the different doses (150, 300, 450 and 
600 mg daily) of pregabalin to ascertain whether there was a significant difference 
regarding their efficacy and tolerability.   
.    
Sensitivity analyses  
No sensitivity analyses were performed.   
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Results  
Description of studies  
This paper includes eight studies which were all full journal publications. They 
included: Arnold et al, [2008; 2014], Crofford et al, 2005; 2008], Mease et al, [2008], 
Nasser et al, [2014], Ohta et al, [2012] and Pauer et al, [2011].  
  
Results of the search  
A total of 26 studies were examined for possible inclusion in this review, 8 of which 
were included and 18 were excluded (see figure 1). Additionally, an on-going study 
was identified on Clinicaltrials.gov (NCT02146430).   
   
Included studies  
A total of 8 studies were included in this review, including 5 studies (3812 
participants) of „classical‟ design [Arnold et al, 2008], [Crofford et al, 2005; Mease et 
al, 2008; Ohta et al, 2012; Pauer et al, 2011] and two studies (687 participants) of an 
„enriched enrolment randomised withdrawal (EERW) design” [Arnold et al, 2014; 
Crofford et al, 2008]. There was one study which compared a single nightly dose of 
pregabalin with twice-daily dosing [Nasser et al, 2014] but was not included in the 
analysis.  
  
• Classical Design: Participants were randomised to pregabalin or placebo at 
the start of the trial using fixed-dose titrations.  
  
• EERW Design: Participants underwent fixed-dose titrations to effect/tolerance 
with pregabalin. Those successfully reaching targets were then randomised a 
second time to continue receiving pregabalin, or to undergo a phased 
withdrawal of pregabalin to placebo.   
  
The vast majority of participants in these studies were female (89%-95%) and of 
Caucasian ethnicity (76%-96%); the mean age of participants was 47 to 50 years.   
  
There was a significant degree of geographical variation with regards to where the 
studies were performed, including Canada and the US, Australia, Asia and Europe.  
All participants were diagnosed with FM in accordance with either the ACR (1990) 
[Wolfe et al, 1990] or ACR (2010) criteria [Wolfe et al, 2010]. Where mentioned, 
participants reported their symptoms to have lasted for an average of ≈4 years.   
  
Of the studies of classical design, three lasted eight weeks [Arnold et al, 2007; 
Crofford et al, 2005; Nasser et al, 2014], and the rest lasted for 13-14 weeks [Arnold 
et al, 2008; Mease et al, 2008; Ohta et al, 2012; Pauer et al, 2011].  
Of the EERW studies, Arnold et al, [2014] had a double-blind treatment period of 13 
weeks following randomisation, and Crofford et al, [2008] had a double-blind 
treatment period of 26 weeks following randomisation.   
  
All the included studies investigated the efficacy and tolerability of pregabalin for the 
treatment of FM. Of the studies of classical design, four tested fixed doses of 
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pregabalin at 300, 450 and 600mg daily against placebo [Arnold et al, 2008; Mease 
et al, 2008; Pauer et al 2011]; one included a 150mg daily dose (in addition to 300 
and 400 mg daily) [Crofford et al, 2005]; and the study by Ohta et al, [2012] utilised a 
flexible dose of 300/450mg daily. Of the EERW studies, Arnold et al, [2014] used 
pregabalin controlled release of doses 330 to 495mg daily, whereas Crofford et al, 
[2008] used fixed doses of 300, 450 and 600mg daily.   
  
Various outcomes were investigated, including pain, fatigue, self-reported sleep 
problems, depression, anxiety and health-related quality of life.   
It is important to note that the studies of EERW design investigated the primary 
outcome as the loss of therapeutic response (LTR). As this outcome is 
fundamentally different to studies of classical design, they are considered separately 
in this review.  
  
Excluded studies  
A total of 18 studies were excluded from this review, including: Arnold et al, [2007; 
2012; 2014b; 2014c; 2015; 2016]; Byon et al, [2010]; Emir et al, [2010]; Hauser et al, 
[2009]; Moore et al, [2007; 2009]; Ohta et al, [2013]; Ramzy et al, [2016]; Roth et al, 
[2012]; Russel et al, [2009], NCT00760474, NCT01268631 and NCT01904097.  The 
reasons for exclusion are described in the characteristics of studies table.   
  
Risk of bias in included studies   
Figure 2 shows the overall „Risk of bias‟ assessment for included studies. „Risk of 
bias assessments for each criterion is shown in figure 3 and the characteristics of 
included studies table.   
  
  
Figure 2: Risk of bias graph: review authors' judgements about each risk of bias item 
presented as percentages across all included studies.  
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Allocation 
Of the included studies (all of which were randomised), five provided descriptions for 
the methods used to generate random sequences. These included: Arnold et al, 
[2008]; Crofford et al, [2005; 2008], Nasser et al, [2014] and Ohta et al, [2012]. 
Arnold et al, [2008], Crofford et al, [2008] and Ohta et al, [2012] provided adequate 
descriptions for the methods used to facilitate allocation concealment, but Crofford et 
al, [2005], Mease et al, [2008], Nasser et al, [2014] and Pauer et al, [2011] did not.   
Blinding  
All the included studies were described as double-blind, however, Crofford et al, 
[2005], Mease et al, [2008] and Pauer et al, [2011] did not provide adequate 
descriptions for the methods used to ensure that participants and personnel were 
unable to differentiate between pregabalin and placebo.  
  
Incomplete outcome data  
Despite the studies by Arnold et al, [2014] and Crofford et al, [2008] whom had no 
missing data, the studies of classical design [Arnold et al, 2008; Crofford et al, 2005; 
Mease et al, 2008; Ohta et al, 2012; Pauer et al, 2011]) used last observation carried 
  
  
  
Figure 3: Risk of bias summary: review authors' judgements about each risk of bias 
item for each included study 
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forward (LOCF) imputation for missing data. Nasser et al, [2014] did not provide any 
information regarding the imputation method for missing data.   
  
Selective reporting  
All the relevant outcomes of the included studies were reported.   
  
Other potential sources of bias  
No other significant sources of bias were noted.   
 
Effects of interventions  
Because the outcomes investigated in studies of classical design and EERW design 
are fundamentally different, they are considered separately.  
1. Studies of classic design  
Pregabalin at varying doses (150, 300, 450 and 600mg) was administered in two 
parts per day and compared with placebo. The study by [Nasser et al, 2014] 
compared the benefit of nightly dosing versus twice daily dosing but found no benefit. 
Efficacy outcomes for the included studies are described below.  
Primary outcomes 
Pregabalin versus placebo: reduction in mean pain score following treatment:  
Five studies with a total of 3252 participants were entered into RevMan5 for analysis 
of the effect of pregabalin on reducing mean pain scores (figure 4). The overall effect 
of pregabalin on the reduction of mean pain scores was statistically significant (SMD: 
-0.26; 95% CI; -0.34 to -0.19; P = <0.00001), but based on Cohen’s categories the 
magnitude of effect following treatment was small (SMD <0.5). There were no 
statistically significant overall differences regarding the efficacy of each dose in 
reducing mean pain scores following treatment (P = 0.64).  
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Figure 4: Forest plot of comparison: Pregabalin versus placebo, outcome 1.1: reduction in 
mean pain scores following treatment.  
  
Pregabalin versus placebo: at least a 50% reduction in pain intensity from baseline 
following treatment:  
Five studies with a total of 3256 participants were entered into RevMan5 for analysis 
of the ability of pregabalin to reduce pain intensity by ≥50% (figure 5). A total of 
514/2319 (22.2%) and 128/937 (13.7%) participants achieved ≥50% pain reduction 
following treatment with either pregabalin or placebo respectively. The overall effect 
of pregabalin in reducing pain intensity by ≥50% was statistically significant (RR: 
1.61; 95% CI; 1.35 to 1.93; P = 0.00001); the NNTB by pregabalin over placebo was 
≈12. There were no statistically significant overall differences regarding the efficacy 
of each dose in achieving a ≥50% reduction in pain intensity following treatment (P = 
0.59).  
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Figure 5: Forest plot of comparison: Pregabalin versus placebo, outcome 1.3:  
participants achieving at least 50% reduction in pain intensity following treatment. 
  
Pregabalin versus placebo: PGIC ‘much or very much improved’ following treatment:  
Five studies with a total of 3183 participants were entered into RevMan5 for analysis 
of the effect of pregabalin on patient global impression of change (PGIC) (figure 6). A 
total of 892/2265 (39.4%) and 256/918 (27.9) participants reported a „much or very 
much improved‟ PGIC following treatment with pregabalin or placebo respectively. 
The overall effect of pregabalin in producing such improvements to PGIC was 
statistically significant (RR: 1.40; 95% CI; 1.25 to 1.58; P = 0.00001); the NNTB by 
pregabalin over placebo was ≈9. There were no statistically significant overall 
differences regarding the efficacy of each dose in achieving a „much or very much 
improved‟ PGIC following treatment (P = 0.84).  
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Figure 6: Forest plot of comparison: Pregabalin versus placebo, outcome 2.1:  
number of participants with PGIC „much or very much improved‟ following treatment. 
  
Pregabalin versus placebo: improvements to self-reported fatigue following 
treatment:   
Five studies with a total of 3195 participants were entered into RevMan5 for analysis 
of the effect of pregabalin in reducing self-reported fatigue (figure 7). The overall 
effect of pregabalin on the reduction of self-reported fatigue was statistically 
significant (SMD: -0.17; 95% CI; -0.25 to -0.09; P = <0.0001), but based on 
Sawilkowsky's expanded categories the magnitude of effect following treatment was 
„very small‟ (SMD <0.2). There were no statistically significant overall differences 
regarding the efficacy of each dose in improving self-reported fatigue (P = 0.49).  
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Figure 7: Forest plot of comparison: Pregabalin versus placebo, outcome 3.1: Change in 
mean multidimensional assessment of fatigue (MAF) score following treatment  
  
Pregabalin versus placebo: improvements to self-reported sleep problems following 
treatment:   
Five studies with a total of 3193 participants were entered into RevMan5 for analysis 
of the effect of pregabalin in reducing self-reported sleep problems (figure 8). The 
overall effect of pregabalin on the reduction of self-reported sleep problems was 
statistically significant (SMD: -0.34; 95% CI; -0.42 to -0.27; P = <0.0001), but based 
on Cohen’s categories the magnitude of effect following treatment was small (SMD 
<0.5). There were no statistically significant overall differences regarding the efficacy 
of each dose in improving self-reported sleep problems following treatment (P = 
0.29).  
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Figure 8: Forest plot of comparison: Pregabalin versus placebo, outcome 4.1:  
Change in mean medical outcomes study (MOS) sleep index scale score following treatment  
    
Pregabalin versus placebo: improvements to self-reported quality of life following 
treatment:   
Four studies with a total of 2724 participants were entered into RevMan5 for analysis 
of the effect of pregabalin in improving self-reported quality of life (figure 9). The 
overall effect of pregabalin on improvements to self-reported quality of life was 
statistically significant (SMD: -0.17; 95% CI; -0.26 to -0.09; P = <0.0001), but based 
on Sawilkowsky's expanded categories the magnitude of effect following treatment 
was very small-small (SMD <0.2). There were no statistically significant overall 
differences regarding the efficacy of each dose in improving self-reported quality of 
life (P = 0.75).  
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Figure 9: Forest plot of comparison: Pregabalin versus placebo, outcome 5.1: Change in 
mean short form 36 (SF-36) score (health related quality of life) following treatment.  
  
Pregabalin versus placebo: improvements to self-reported anxiety following 
treatment:   
Five studies with a total of 3215 participants were entered into RevMan5 for analysis 
of the effect of pregabalin on improvements to self-reported anxiety (figure 10). The 
overall effect of pregabalin on improvements to self-reported anxiety was statistically 
significant (SMD: -0.13; 95% CI; -0.21 to -0.06; P = <0.0007), but based on 
Sawilkowsky's expanded categories the magnitude of effect following treatment was 
very small (SMD: <0.2). There were no statistically significant overall differences 
regarding the efficacy of each dose in reducing self-reported anxiety (P = 0.65).  
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Figure 10: Forest plot of comparison: Pregabalin versus placebo, outcome 6.1: Change in 
HADS anxiety score following treatment.  
Pregabalin versus placebo: improvements to self-reported depression following 
treatment:   
Five studies with a total of 3209 participants were entered into RevMan5 for analysis 
of the effect of pregabalin on improvements to self-reported depression (figure 11). 
The overall effect of pregabalin on improvements to depression was statistically 
significant (SMD: -0.10; 95% CI; -0.18 to -0.02; P=0.01), but based Sawilkowsky's 
expanded categories the magnitude of effect following treatment was very small 
(SMD: <0.2). There were no statistically significant overall differences regarding the 
efficacy of each dose in reducing self-reported depression (P = 0.96) following 
treatment.  
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Figure 11: Forest plot of comparison: Pregabalin versus placebo, outcome 6.2: Change in 
HADS depression score following treatment.   
Secondary outcomes:  
Pregabalin versus placebo: at least a 30% reduction in pain intensity from baseline 
following treatment:  
Five studies with a total of 3259 participants were entered into RevMan5 for analysis 
of the ability of pregabalin to reduce pain intensity by ≥30% (figure 12). A total of 
928/2319 (40.0%) and 274/940 (29.1%) participants achieved ≥30% pain reductions 
following treatment either pregabalin or placebo respectively. The overall effect of 
pregabalin in reducing pain intensity by ≥30% was statistically significant (RR: 1.38; 
95% CI; 1.23 to 1.55; P = 0.00001); the NNTB by pregabalin over placebo was ≈9. 
There were no statistically significant overall differences regarding the efficacy of 
each dose in in achieving a ≥30% reduction in pain intensity following treatment (P = 
0.79).  
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Figure 12: Forest plot of comparison: Pregabalin versus placebo, outcome 1.3:  
participants achieving at least 30% reduction in pain intensity following treatment. 
  
Pregabalin versus placebo: incidence of participant withdrawal due to adverse effects 
following treatment:  
Five studies with a total of 3259 participants were entered into RevMan5 for analysis 
of the safety and tolerability of pregabalin, as judged by the number of participant 
withdrawals following treatment (figure 13). A total of 449/2317 (19.4%) and 104/942 
(11.0%) participants withdrew from trials following treatment with pregabalin or 
placebo respectively. The overall effect of pregabalin in causing participant 
withdrawal due to adverse effects was statistically significant (RR: 1.75; 95% CI; 
1.42 to 2.15; P = 0.00001); the NNTH by pregabalin over placebo was ≈12. There 
was a statistically significant overall difference regarding the propensity of each dose 
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to result in participant withdrawal due to adverse effects following treatment (P = 
0.04), and this was most evident in the 600mg daily treatment arm.  
 
Figure 13: Forest plot of comparison: Pregabalin versus placebo, outcome 7.2: incidence of 
participant withdrawal due to adverse effects.  
Pregabalin versus placebo: incidence of ‘serious adverse effects’ following 
treatment:  
Four studies with a total of 2729 participants were entered into RevMan5 for analysis 
of the safety and tolerability of pregabalin, as judged by the incidence of „serious 
adverse effects‟ following treatment (figure 14). A total of 100/1921 (5.2%) and 
33/808 (4.1%) participants experienced „serious adverse effects‟ following treatment 
with pregabalin or placebo respectively. The overall effect of pregabalin in causing 
„serious adverse effects‟ was not statistically significant (RR: 1.06; 95% CI; 0.73 to 
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1.53; P = 0.31), and there were no statistically significant overall differences 
regarding the propensity of each dose to cause „serious adverse effects‟ following 
treatment (P = 0.82).  
 
 
Figure 14: Forest plot of comparison: Pregabalin versus placebo, outcome 7.3: incidence of 
serious adverse effects following treatment.  
  
Pregabalin versus placebo: incidence of specific adverse effects (dizziness) following 
treatment:   
Five studies with a total of 3257 participants were entered into RevMan5 for analysis 
of the incidence of dizziness following treatment with pregabalin (figure 15). A total of 
883/2319 (38%) and 87/938 (9.28%) participants experienced dizziness following 
treatment with pregabalin or placebo respectively. The overall effect of pregabalin in 
causing dizziness was statistically significant: (RR: 3.89; 95% CI; 3.16 to 4.78; P = 
0.00001); the NNTH by pregabalin over placebo was ≈3. There were no statistically 
significant overall differences regarding the propensity of each dose to cause 
dizziness (P = 0.62) following treatment.  
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Figure 15: Forest plot of comparison: Pregabalin versus placebo, outcome 8.1: incidence of 
dizziness following treatment.  
  
Pregabalin versus placebo: incidence of specific adverse effects (somnolence) 
following treatment:  
Five studies with a total of 3257 participants were entered into RevMan5 for analysis 
of the incidence of somnolence following treatment with pregabalin (figure 16). A 
total of 543/2319 (23.4%) and 79/938 (8.4%) participants experienced somnolence 
following treatment with pregabalin or placebo respectively. The overall effect of 
pregabalin in causing somnolence was statistically significant (RR: 3.42; 95% CI; 
2.71 to 4.32; P = 0.00001); the NNTH by pregabalin over placebo was ≈7. There 
were no statistically significant overall differences regarding the propensity of each 
dose to cause somnolence (P = 0.31) following treatment.  
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Figure 16: Forest plot of comparison: Pregabalin versus placebo, outcome 8.2: incidence of 
somnolence following treatment.   
  
2. Studies of EERW design   
Two studies of enriched enrolment randomised withdrawal (EERW) design were 
included in this review [Arnold et al, 2014; Crofford et al, 2008]. Although both 
studies screened participants for eligibility using the same inclusion criteria as the 
studies of classic design, they used a fundamentally different experimental design. 
Unlike the studies of classical design, eligible participants were first administered 
single-blind pregabalin at increasing dosage over three weeks to ascertain the 
maximum tolerated dose (MTD). In this regard, both studies required at least a 50% 
reduction in pain intensity from baseline within the next 3 weeks; the study by 
Crofford et al, [2008] also required significant improvements to the patient global 
impression of change (PGIC). Participants achieving these outcomes (responders) 
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were then eligible for entry into the double-blind treatment phase which involved 
randomisation to either a double-blind treatment with maintenance dose pregabalin, 
or a phased-dose reduction to placebo over the following week. Treatment with 
either intervention was then continued for 13 weeks [Arnold et al, 2014] or 26 weeks 
[Crofford et al, 2008] respectively.  
It is important to note that different doses of pregabalin were employed between the 
two studies. Arnold et al, [2014] used pregabalin controlled release (CR) of doses  
330 to 495mg daily, whereas Crofford et al, [2008] used fixed doses of 300, 450 and 
600mg daily.  
In both studies, the primary outcome was the loss of therapeutic response (LTR). 
Arnold et al, [2014] defined the LTR as <30% pain reduction relative to the baseline 
value recorded following single-blind treatment; or the incidence of patient 
withdrawal due to lack of efficacy or adverse-effects experienced during the double-
blind treatment phase. Conversely, Crofford et al, [2008] described LTR as <30% 
reduction in visual pain analogue scale (VAS) score from the baseline value for two 
consecutive recordings during the double-blind phase; or following the observation 
that the symptoms of FM worsened with treatment, ultimately requiring the use of 
alternative medication.  
 
Using guidance from Derry et al, [2016], the primary outcome for these studies was 
defined in this review by the maintenance of therapeutic response (MTR). MTR is a 
positive value which is essentially the opposite of LTR; it encompasses both a ≥30% 
reduction in pain intensity and requires the continuation of treatment (all-cause 
withdrawal being considered a treatment failure) with any adverse effects being 
tolerable [Derry et al, 2016]. Using this definition, the results of both studies can be 
compared with each other, and to outcomes described in the studies of classical 
design (i.e. at least 30% reduction in pain intensity following treatment).  
EERW outcomes 
Pregabalin versus placebo: maintenance of therapeutic effect (MTR):   
Two studies with a total of 687 participants were entered into RevMan5 for analysis 
of the maintenance of therapeutic effect (MTR) following treatment with pregabalin 
(figure 17). A total of 136/342 (39.8%) and 72/345 (20.9%) participants achieved 
MTR following treatment either pregabalin or placebo respectively. The overall effect 
of pregabalin in achieving MTR was statistically significant (RR: 1.9; 95% CI; 1.5 to 
2.4; P = 0.00001). The NNTB by pregabalin over placebo was ≈5.  
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Figure 17: Forest plot of comparison: Pregabalin versus placebo, outcome 9.1: participants 
achieving a maintained therapeutic response following treatment.  
 
Pregabalin versus placebo: incidence of participant withdrawal for any reason:  
Two studies with a total of 687 participants were entered into RevMan5 for analysis 
of the incidence of all-cause withdrawal following treatment with pregabalin (figure 
18). A total of 189/342 (55.3%) and 243/345 (70.4%) participants withdrew from 
study following treatment either pregabalin or placebo respectively. The overall effect 
of pregabalin in causing all-cause withdrawal was not statistically significant (RR: 
0.79; 95% CI; 0.71 to 0.89; P = 0.0001). The NNTH by pregabalin over placebo was 
≈7.  
 
Figure 18: Forest plot of comparison: Pregabalin versus placebo, outcome 9.2: incidence of 
all-cause withdrawal following treatment.  
  
Pregabalin versus placebo: incidence of adverse effects following treatment:  
Two studies with a total of 687 participants were entered into RevMan5 for analysis 
of the safety and tolerability of pregabalin, as judged by the incidence of adverse 
effects following treatment (figure 19). A total of 222/342 (64.9%) and 168/345 
(48.7%) participants experienced at least one adverse effect following treatment with 
pregabalin or placebo respectively. The overall effect of pregabalin in causing 
adverse effects was statistically significant (RR: 1.3; 95% CI; 1.2 to 1.5; P = 
0.000028). The NNTH by pregabalin over placebo was ≈6.  
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Figure 19: Forest plot of comparison: Pregabalin versus placebo, outcome 9.3: incidence of 
serious adverse effects following treatment.  
Discussion  
Summary of main results  
This review aimed to investigate the efficacy and tolerability of pregabalin for the 
management of FM. The results of this review were derived from 8 studies of both 
classical and enriched enrolment with randomised withdrawal (EERW) design; all of 
which employed the same inclusion criteria and investigated similar outcome 
measures.  
Although typically characterised by chronic diffuse pain, FM is associated with a 
constellation of symptoms. Subsequently, this review attempted to collate data for 
multiple outcomes for different symptoms to best reflect the condition as a whole. 
This means that although pain scores were included as primary outcomes, sleep 
disturbances, fatigue, anxiety, depression, health-related quality of life and patient 
impression of change were also investigated. Additionally, the safety and tolerability 
of pregabalin was determined by the incidence of adverse-effects (including 
somnolence and dizziness) following treatment, as well as the incidence of 
participant withdrawal as a result.  
1. Studies of classical design:  
Five studies (3283 participants) of classical design were included in this review.   
Of the studies of classical design, Arnold et al, [2008], Crofford et al [2005], Mease et 
al, [2008], Ohta et al, [2012] and Pauer et al, [2011] investigated the efficacy and 
tolerability of pregabalin for the management of FM syndrome and were included for 
quantitative analysis.  Several doses of pregabalin were compared with a placebo for 
the outcomes described, including fixed doses of 150, 300, 450 and 600mg daily. 
Only one study [Crofford et al, 2005] investigated the efficacy and tolerability of 
150mg pregabalin daily, and the study by Ohta et al, [2012] was slightly different in 
the fact it used a „flexible dose‟ of either 300 or 450mg daily. For this reason, it was 
considered a discrete dose in this review.    
Overall, the use of pregabalin for FM produced a small overall benefit to pain and 
sleep problems; however, its effect on fatigue, anxiety, depression and health-related 
quality of life was less profound. For the dichotomous outcomes, the numbers 
needed to treat for an additional beneficial outcome (NNTB) were ≈12 for a 50% 
reduction in pain intensity, and ≈9 for a 30% reduction in pain intensity. Furthermore, 
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the NNTB for a „much or very much improved patient global impression of change 
(PGIC) was ≈9. Of the meta-analyses for efficacy, all of the results were statistically 
significant. Generally speaking there was no dose-response relationship for efficacy 
outcomes, although 450mg daily tended to yield the best results.  
With regards to the safety and tolerability of pregabalin, the incidence of participant 
withdrawal is significantly higher with pregabalin than placebo. The numbers needed 
to treat for an additional harmful outcome (NNTH) by pregabalin over placebo for 
participant withdrawal due to adverse effects was ≈12. Moreover, there was a 
statistically significant difference between the incidence of specific adverse effects, 
namely somnolence and dizziness between pregabalin and placebo. The NNTH by 
pregabalin over placebo for the incidence of somnolence and dizziness was ≈7 and 
≈3 respectively. Of the meta-analyses for safety and tolerability, all of the results 
were statistically significant except for the incidence of „serious adverse effects‟. 
Generally speaking there was no dose-response relationship for safety and 
tolerability, although adverse effects tended to occur most frequently in the 600mg 
daily treatment arm.    
2. Studies of enriched enrolment with randomised withdrawal (EERW) design:  
Two studies (1492 participants) of enriched enrolment with randomised withdrawal 
(EERW) design were included in this review. However, due to the fact participants 
were first required to undergo a single-blind titration period, only 687 of these 
participants were deemed eligible for entry into the double-blind treatment phase. 
Both trials investigated the efficacy and tolerability of pregabalin for the management 
of FM syndrome and were included for quantitative analysis.  
As with the studies of classical design, several doses of pregabalin were compared 
with a placebo for the outcomes described. However, different dosing regimens were 
employed between the two studies. Arnold et al, [2014] used pregabalin controlled 
release (CR) of doses 330 to 495mg daily, whereas Crofford et al, [2008] used fixed 
doses of 300, 450 and 600mg daily.   
The primary efficacy outcome for these studies was the maintenance of therapeutic 
response (MTR), defined by the number of participants achieving at least a 30% 
reduction in pain intensity without withdrawal for the duration of the trial(s). The 
benefit of pregabalin in this regard was statistically significant, with ≈20% more 
individuals achieving MTR with pregabalin than placebo. Furthermore, the numbers 
needed to treat for an additional beneficial outcome (NNTB) by pregabalin over 
placebo was ≈5. Considering that only half (687/1492) of participants entered the 
double-blind trial, assuming all participants were eligible the NNTB would have been 
≈10 – and this is comparable to the results of studies classical design where the 
NNTB by pregabalin over placebo was ≈9 for 30% pain reduction.   
With regards to the safety and tolerability of pregabalin, the incidence of adverse 
effects following treatment was significantly higher with pregabalin than placebo. 
Approximately 15% more participants in the pregabalin group experienced adverse 
effects compared to the placebo group; the NNTH by pregabalin over placebo was 
≈6.  
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Overall completeness and applicability of the evidence  
The studies included in this review provide a current and accurate representation of 
the efficacy and tolerability of pregabalin for the treatment of FM. However, there are 
certain limitations regarding its external validity. 
   
Firstly, although the participants of included studies were typically representative of 
FM sufferers in general (i.e. primarily middle-aged women of Caucasian ethnicity), 
the lack of variation amongst them means it is not necessarily possible to extrapolate 
these results to the general population. For example, male participants were not 
excluded from this review; however, they were not well represented by the studies 
included. A possible reason for this may reside in how the condition is diagnosed, as 
following the introduction of the 2010 diagnostic criteria [Wolfe et al, 2010] the 
proportion of female: male sufferers was estimated to have changed from ≈30:1 (as 
with the 1990 ACR classification) to ≈2:1. [Derry et al, 2016] The included studies did 
not employ stringent guidelines regarding how FM was diagnosed, simply stating 
that participants were diagnosed using either the 1990 or 2010 diagnostic criteria. 
Subsequently, it is advised that future studies investigating FM should attempt to be 
more inclusive to male participants, and restrict eligible participants to those 
diagnosed with 2010 diagnostic criteria, as opposed to the 1990 diagnostic criteria.  
Furthermore, these results cannot be applied to children or adolescents as they were 
excluded from this review. The reason for this was due to the fact juvenile-onset 
fibromyalgia (JFM) is a relatively rare phenomenon which is difficult to diagnose 
[Kashikar-Zuck et al, 2014] and was only investigated by a limited number of studies 
which were generally <8 weeks in duration.  
  
Secondly, due to the fact that stringent inclusion criteria were employed by this 
study, there is possibility that the results of this review cannot necessarily be applied 
to the wider population of FM sufferers. For example, as FM is often a comorbid 
condition (i.e. with chronic depression), and this review did not permit the use of 
concurrent medication (besides paracetamol and aspirin), otherwise eligible 
participants were not included in studies if they were unwilling or unable to stop 
taking their medication.  As described by Üçeyler et al, [2013], this may have biased 
participant selection towards individuals who could manage their symptoms well. 
Additionally, due to the fact that participants with concurrent neuropathic or 
rheumatic diseases (i.e. rheumatoid arthritis) were excluded from this review, 
patients who may have developed FM as a consequence of another condition 
(secondary fibromyalgia) were also excluded from this review.   
Furthermore, although a range of doses have been investigated for the outcomes 
described, generally speaking there was no significant difference between them with 
regards to efficacy and tolerability. This may be due to the fact that the majority of 
the included studies were of insufficient duration to ascertain the effects of their long-
term use. However, the study by Crofford et al, [2008] had a duration of 6 months 
and did not report any significantly different results to the studies of shorter duration, 
indicating that pregabalin is in fact effective for long term use. This observation is 
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supported by the findings of extension studies which demonstrated the efficacy and 
tolerability of pregabalin for up to one year [Arnold et al, 2012; Ohta et al, 2013].  
 
Quality of the evidence  
The included studies were all described as being randomised and double-blind. 
Studies had a minimum duration of 8 weeks, and included samples of adequate size 
to minimise the risk of random chance errors or small study biases [Dechartres et al,  
2013]. However, the studies of classical design employed a „last observation carried 
forward‟ (LOCF) imputation for missing data (i.e. in the instance of participant 
withdrawal, pain scores at the time of withdrawal were recorded as if they had been 
scored at the end of the trial). Unfortunately, LOCF imputation has the potential to 
over-estimate and/or underestimate the magnitude of treatment effect, and 
subsequently the results of these studies were considered second-tier evidence. 
Conversely, the studies of EERW design did not require imputation, and were 
therefore considered first-tier evidence. However, due to the fact that access to the 
results of these studies was only possible via the review by Derry et al, [2016], it is 
possible that negative study results may not have been published, or the data may 
have been manipulated in some way.  
  
Potential biases in the review process 
All relevant outcomes have been reported where possible. Despite the results EERW 
studies which were obtained through the results section of a review by Derry et al, 
[2016], the data was obtained from the original papers and not altered in any way. 
No other considerable sources of bias in the review process are known.    
 
Agreements and disagreements with other studies or reviews   
The results of this review are in significant agreement with past reviews which 
investigated similar outcomes. For example, the systematic review by Straube et al, 
[2010] used 4/6 of the studies of classical design ([Arnold et al, 2008; Crofford et al, 
2005; Mease et al, 2008; Pauer et al, 2011]) and reported that pregabalin had a 
significant benefit over placebo for both the dichotomous and continuous efficacy 
outcomes reported in this review. Additionally, the use of Cohen’s categories (as well 
as Sawilkowsky's expanded categories) to define the magnitude of effect for 
continuous outcomes produced results that were in considerable agreement with that 
of Moore et al, [2009], who also observed that most participants experienced only a  
„small‟ benefit for the outcomes described.    
 
For the studies of EERW design ([Arnold et al, 2014; Crofford et al, 2008]) which 
investigated the maintenance of therapeutic response (MTR) as the primary 
outcome, the numbers needed to treat (NNT) obtained for efficacy outcomes were in 
considerable agreement with a previous review by Derry et al, [2016], suggesting 
that this review had sound statistical methodology.   
 
Despite the fact 450mg daily seemed to be the most efficacious dose (possibly due 
to the number of participants), there was generally no significant difference regarding 
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the efficacy of pregabalin for the outcome described, and this is consistent with the 
findings of Tzellos et al, [2010] and Uceyler et al, [2013].   
  
With regards to the safety and tolerability of pregabalin, and with the exception of 
serious adverse effects (for which there was no significant difference), there was a 
statistically significant increase in the incidence of adverse events and participant 
withdrawal following treatment with pregabalin. The incidence of named adverse 
effects (somnolence and dizziness) also correlated with this trend. Although there 
was generally no dose-response relationship, they tended to occur most frequently in 
the 600mg daily treatment arm. These findings were also consistent with the results 
of past reviews [Derry et al, 2016; Straube et al, 2010; Tzellos et al, 2010; Uceyler et 
al, 2013].  
    
Authors conclusions 
1. Implications for practice  
FM is a condition characterised primarily by chronic pain, but also by symptoms 
including: sleep problems, fatigue, disability, anxiety and depression. Although 
pregabalin has the potential to significantly improve such symptoms, generally 
speaking changes were not substantial and observed in a minority of participants.  
Furthermore, the use of pregabalin is associated with a number of side effects (i.e. 
somnolence and dizziness), albeit fairly mild, which occur more frequently at higher 
doses. Although 450 mg daily may achieve an equitable balance between efficacy 
and tolerability, the possible benefits and harms of pregabalin should be discussed 
between the patient and doctor prior to prescription.  Treatment regimens should be 
considered on the basis of individual circumstance and closely monitored thereafter 
to ensure the safety of the patient [Gahr et al, 2013].  
 
2. Implications for research 
Recommendations for future research on the efficacy and tolerability of pregabalin 
for the management of FM include:   
• Comparison with an active comparator (i.e. other anti-convulsants): This is 
recommended as it is more significant to clinical practice (i.e. where multiple 
treatment options are possible).   
 
• Inclusion of co-morbid patients: This is recommended as it is more 
significant to clinical practice and better representative of the general 
population.   
 
• Gradual dosing regimen: Clinical trials employ rapid dose increments, and 
this is not necessarily representative of clinical practice where dosing is 
more gradual.   
 
• Variation in dosing regimen: Although the study by [Nasser et al, 2014] 
found no benefit between nightly dosing versus twice daily dosing 
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pregabalin, it had a relatively small number of participants (177) and did find 
a decrease in the incidence of adverse-effects in the nightly-dosing 
treatment arm. As there is little research into this area, it should be 
investigated further to substantiate or dispute such findings, as variation to 
dosing regimen may be appropriate in some cases (i.e. for comorbid 
patients who take multiple mediations).   
 
• Post-hoc baseline observation carried forward (BOCF) imputation: BOCF 
imputation uses the final response from the patient, regardless of the reason 
for patient drop-out or the scores at the time of withdrawal for missing 
endpoint data. This is considered more conservative than LOCF imputation 
as it is less likely to overestimate the magnitude of treatment effect. It should 
therefore be considered for post-hoc analyses to strengthen the significance 
of findings and any conclusions made.  
   
    
Characteristics of studies  
Characteristics of included studies (ordered by study ID) 
 
 1. Arnold 2008  
Methods  14-week randomised, placebo-controlled, double-blind, parallel-group trial.  
  
  
Participants  
Fibromyalgia according to ACR classification and pain of at least 40/100 mm and pain score 
≥ 4 on the 11-point numerical rating scale in the week before randomisation N = 750 (745 
analysed)  
Mean age 50 years, 95% female, 91% white  
Baseline mean pain score: 6.7/10  
  
  
Interventions  
1-week single-blinded placebo run-in phase, 2-week double-blinded dose escalation phase, 
12week fixed dose  
Pregabalin 300 mg daily, n = 183  
Pregabalin 450 mg daily, n = 190  
Pregabalin 600 mg daily, n = 188  
Placebo daily, n = 184  
  
  
  
  
Outcomes  
Pain: Daily diary mean pain (NRS 0-10); 30%/50% reductions in pain intensity 
Fatigue: MAF (NRS 1-50)  
Sleep: MOS Sleep Problems Index (NRS 0-100)  
Depression: HADS (NRS 0-21)  
Anxiety: HADS (NRS 0-21)  
Health Related Quality of Life: SF-36 (NRS 50-0)  
Patient-perceived improvement: PGIC (1-7)  
AEs: Observed or spontaneously reported AEs; laboratory results, physical examinations, ECG  
Notes  Pfizer sponsored. LOCF used to account for missing data and participant withdrawals  
  
Risk of bias table  
Bias  Authors Judgement  Support for judgement  
Random sequence generation (selection 
bias)  
Low risk  "Random assignment to treatment regimens used a  
1:1:1:1 ratio according to a computer-generated 
pseudorandom code using the method of random  
permuted blocks (i.e., block size of 4)”  
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Allocation concealment (selection bias)  Low risk  "Random assignment was managed by a 
telerandomisation system”  
Blinding of participants and personnel 
(performance bias  
Low risk  "To maintain the blinding, all doses of pregabalin and 
placebo were packaged using identical encapsulation.  
At each visit, all patients received 1 bottle of capsules 
that were identical in appearance and taste from which  
they took 1 capsule twice a day"  
Blinding of outcome assessment (detection 
bias)  
Low risk  "To maintain the blinding, all doses of pregabalin and 
placebo were packaged using identical encapsulation.  
At each visit, all patients received 1 bottle of capsules 
that were identical in appearance and taste from which  
they took 1 capsule twice a day"  
Incomplete outcome data (attrition bias)  Unclear risk  LOCF Imputation.  
Selective reporting (reporting bias)    
Low risk  
All relevant outcomes were reported.  
  
Other bias  Unclear risk  Size - 50 to 199 participants were selected per 
treatment arm  
  
  
2. Arnold 2014  
Methods  A 13-week multicentre, controlled-release, double-blind, placebo-controlled, EERW trial  
  
  
Participants  
Fibromyalgia according to ACR classification and a pain score ≥ 4 on the 11-point numerical 
rating scale prior to randomisation  
N = 441 entered dose-titration phase, 121 randomised to double-blind phase  
Mean age 50 years, 91% female, 90% white  
Baseline mean pain score: 6.8/10  
  
  
Interventions  
4 Phases: (1) Baseline [1 week], (2) single-blind (participants blinded) treatment [6 weeks], (3)  
double-blind treatment [13 weeks] and (4) a double-blind taper period [1 
week] Pregabalin controlled release 330 to 495 mg daily, N=63 Placebo, 
N=58  
  
  
Outcomes  
Pain intensity on an 11-point numerical rating scale using daily pain diary 
Adverse effects  
Withdrawals  
Notes  Pfizer sponsored  
  
Risk of bias table  
Bias  Authors Judgement  Support for judgement  
Random sequence generation (selection 
bias)  
Unclear risk  Stated to be randomised ("randomly assigned") 
however the method of sequence generation is not  
described  
Allocation concealment (selection bias)  Low risk  "telephone using the interactive voice recognition 
system (IVRS)"  
Blinding of participants and personnel 
(performance bias  
Low risk  Stated to be double-blind; used a matching placebo or 
optimal open-label dosage of pregabalin  
  
Blinding of outcome assessment (detection 
bias)  
Low risk  Stated to be double-blind; used a matching placebo or 
optimal open-label dosage of pregabalin  
  
Incomplete outcome data (attrition bias)  
Low risk  All participants were included in analysis  
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Selective reporting (reporting bias)  
  
Low risk  
All relevant outcomes were reported.  
  
Other bias  Unclear risk  Size - 50 to 199 participants were selected per 
treatment arm  
   
3. Crofford 2005  
Methods  8-week multicentre, randomised, double-blind, placebo-controlled, parallel-group trial  
  
  
  
Participants  
Fibromyalgia according to ACR classification. Pain of at least 40/100 mm and pain diary score  
≥ 4 on 11-point numerical rating scale in week before randomisation N 
= 529  
Mean age 49 years, 92% female, 93% white  
Baseline mean pain score: 7/10  
  
  
Interventions  
8-week fixed dose (except for pregabalin 450 mg/day who received 300 mg/day for the first 
3 days, and then 450 mg/day) Pregabalin 150 mg daily, n = 132  
Pregabalin 300 mg daily, n = 134  
Pregabalin 450 mg daily, n = 132  
Placebo daily, n = 131  
  
  
Outcomes  
Pain: SF-MPQ (VAS 0-100)  
Fatigue: MAF (NRS 1-50)  
Sleep: MOS Sleep Problems Index (NRS 0-100)  
Depression: HADS (NRS 0-21)  
Anxiety: HADS (NRS 0-21)  
Health Related Quality of Life: Not assessed  
Patient-perceived improvement: PGIC (1-7)  
AEs: Observed or spontaneously reported AEs; laboratory results, physical examinations, ECG  
Notes  Pfizer sponsored. LOCF used to account for missing data and participant’s withdrawals.  
  
Risk of bias table  
Bias  Authors Judgement  Support for judgement  
Random sequence generation (selection 
bias)  
Low risk  "Randomization was by computer-generated code 
using a block size of 8"  
Allocation concealment (selection bias)  Unclear risk  Not described  
Blinding of participants and personnel 
(performance bias  
Unclear risk  Double-Blind - no further details of methods used.  
  
Blinding of outcome assessment (detection 
bias)  
Unclear risk  Double-Blind - no further details of methods used.  
  
Incomplete outcome data (attrition bias)  
Unclear risk  LOCF Imputation.  
  
Selective reporting (reporting bias)  
  
Low risk  
All relevant outcomes were reported  
Other bias  Unclear risk  Size - 50 to 199 participants were selected per 
treatment arm  
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4. Crofford 2008  
  
  
Methods  
26-week randomised, double-blind, placebo-controlled, parallel-group, EERW trial. Participants 
initially screened for response (≥ 50% decrease in pain and PGIC of much or very much 
improved). Responders to initial titration selected for randomisation to placebo or continued 
use of maximum tolerated dose (MTD).   
  
  
Participants  
Fibromyalgia according to ACR classification and pain of at least 40/100 mm in week before 
randomisation, with 6 months of follow-up  
N = 1051 entered open-label phase (6 weeks); 566 randomised to double-blind phase (26 
weeks)  
Mean age 49 years, 93.5% female, 90% white  
Baseline mean pain score: 78/100  
  
Interventions  
Pregabalin titrated to a maximum of 600 mg daily, n = 279 (300 mg = 63; 450 mg = 73; 600 mg 
= 143)  
Placebo daily, n = 287  
  
  
Outcomes  
Loss of therapeutic response (worsening of pain or other symptoms, pain reduction less 
than 30% of baseline on several occasions, withdrawal) measured in days Adverse events  
Withdrawals  
Notes  Pfizer sponsored  
  
Risk of bias table  
Bias  Authors Judgement  Support for judgement  
Random sequence generation (selection 
bias)  
Low risk  "A tele-randomisation system randomised responders 
to either matching placebo or optimal open label  
dosage of pregabalin (1:1)"  
Allocation concealment (selection bias)  Low risk  A tele-randomisation system was used.  
Blinding of participants and personnel 
(performance bias  
Low risk  "matching placebo or optimal open-label dosage of 
pregabalin"  
  
Blinding of outcome assessment (detection 
bias)  
Low risk  "matching placebo or optimal open-label dosage of 
pregabalin"  
  
Incomplete outcome data (attrition bias)  
Low risk  All participants were included in analysis.  
  
Selective reporting (reporting bias)  
Low risk  All relevant outcomes were reported.  
Other bias  Low risk  No other sources of significant bias were observed  
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5. Mease 2008  
Methods  12-week multicentre, randomised, double-blind, placebo-controlled, parallel-group trial.  
  
  
Participants  
Fibromyalgia according to ACR classification and pain of at least 40/100 mm in week before 
randomisation  
N = 748  
Mean age 49 years, 94% female, 90% white  
Baseline mean pain score: 7.1/10  
  
Interventions  
1-week dose escalation (all participants started at 150 mg), 12 weeks with fixed dose 
Pregabalin 300 mg daily, n = 185  
Pregabalin 450 mg daily, n = 183  
Pregabalin 600 mg daily, n = 190  
Placebo daily, n = 190  
  
  
Outcomes  
Pain: Daily diary mean pain (NRS 0-10); 30%/50% reductions in pain intensity 
Fatigue: MAF (NRS 1-50)  
Sleep: MOS Sleep Problems Index (NRS 0-100)  
Depression: HADS (NRS 0-21)  
Anxiety: HADS (NRS 0-21)  
Health Related Quality of Life: SF-36 (NRS 50-0)  
Patient-perceived improvement: PGIC (1-7)  
AEs: Observed or spontaneously reported AEs; laboratory results, physical examinations, ECG  
Notes  Pfizer sponsored. LOCF used to account for missing data and participant withdrawals.  
  
Risk of bias table  
Bias  Authors Judgement  Support for judgement  
Random sequence generation (selection 
bias)  
Unclear risk  Stated to be randomised however the method of 
sequence generation is not described  
Allocation concealment (selection bias)  Unclear risk  Not described  
Blinding of participants and personnel 
(performance bias  
Unclear risk  Double-Blind - no further details of methods used.  
  
Blinding of outcome assessment (detection 
bias)  
Unclear risk  Double-Blind - no further details of methods used.  
  
Incomplete outcome data (attrition bias)  
Unclear risk  LOCF imputation.  
  
Selective reporting (reporting bias)  
Low risk  All relevant outcomes were reported.  
Other bias  Unclear risk  Size - 50 to 199 participants were selected per 
treatment arm  
       
6. Nasser 2014  
Methods  8-week multicentre, randomised, double-blind comparison of 2 dosing schedules (nightly 
versus twice daily.  
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Participants  
Females with fibromyalgia according to ACR classification and pain diary score ≥ 4 on 11-point 
numerical rating scale  
N = 177  
Mean age 50 years, 96% white  
Baseline mean pain score: 7.1/10  
  
Interventions  
300 mg dose taken once nightly (placebo in the morning) or as a divided dose, twice daily Once 
nightly (week 1: 75 mg; week 2: 150 mg; week 3: 225 mg; weeks 4 to 8: 300 mg; week 9: taper 
dose, n = 89)  
Twice daily (week 1: 75 mg x 2; week 2 to 8: 150 mg x 2; week 9: taper dose, n = 88)  
  
  
Outcomes  
Pain: Daily diary mean pain (NRS 0-10)  
Fatigue: VAS (0-100 mm)  
Sleep: VAS sleep disturbance (0-100 mm)  
Patient-perceived improvement: PGIC (1-7)  
AEs: Observed or spontaneously reported AEs; laboratory results, physical examinations, ECG  
Notes  Pfizer sponsored.  
  
Risk of bias table  
Bias  Authors Judgement  Support for judgement  
Random sequence generation (selection 
bias)  
Low risk  "Randomised using a random number generator to 
assign patients to either group"  
Allocation concealment (selection bias)  Unclear risk  Not described  
Blinding of participants and personnel 
(performance bias  
Low risk  Double blind; placebo replaced morning dose for 
nightly dosing  
  
Blinding of outcome assessment (detection 
bias)  
Low risk  Double blind; placebo replaced morning dose for 
nightly dosing  
  
Incomplete outcome data (attrition bias)  
Unclear risk  LOCF imputation.  
  
Selective reporting (reporting bias)  
Unclear risk  All relevant outcomes were reported.  
Other bias  Unclear risk  Size - 50 to 199 participants were selected per 
treatment arm  
      
7. Ohta 2012  
Methods  A 12-week multicentre, randomised, double-blind, placebo-controlled trial  
  
  
Participants  
Japanese participants with fibromyalgia according to ACR classification. Pain of ≥ 40/100 mm 
and pain diary score ≥ 4 on 11-point numerical rating scale before randomisation  
N = 498  
Mean age 48 years, 89% female  
Baseline mean pain score: 6.5/10  
  
Interventions  
4 phases: 1-week single-blind run-in period, 3-week dose escalation, 12-week fixed dose at 
300 or 450 mg, 1-week taper phase  
Pregabalin all doses, n = 250  
Placebo, n = 248  
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Outcomes  
Pain: Daily diary mean pain (NRS 0-10); 30%/50% reductions in pain intensity  
Fatigue: FIQ Fatigue single scale (VAS 0-10)  
Sleep: MOS Sleep Problems Index (NRS 0-100)  
Depression: HADS (NRS 0-21)  
Anxiety: HADS (NRS 0-21)  
Health Related Quality of Life: SF-36 (NRS 50-0)  
Patient-perceived improvement: PGIC (1-7)  
AEs: Observed or spontaneously reported AEs; laboratory results, physical examinations, ECG  
Notes  Pfizer sponsored.  
  
Risk of bias table  
Bias  Authors Judgement  Support for judgement  
Random sequence generation (selection 
bias)  
Low risk  "Randomisation control system (IMPALA), which 
provided subject randomisation numbers"  
Allocation concealment (selection bias)  Unclear risk  "Randomisation control system (IMPALA), which 
provided subject randomisation numbers"  
Blinding of participants and personnel 
(performance bias  
Low risk  "Pregabalin and placebo capsules were prescribed by 
the investigator using blinded drug numbers issued by  
IMPALA"  
"Identical placebo"  
  
Blinding of outcome assessment (detection 
bias)  
Low risk  "Pregabalin and placebo capsules were prescribed by 
the investigator using blinded drug numbers issued by 
IMPALA"  
"Identical placebo"  
  
Incomplete outcome data (attrition bias)  
Unclear risk    
LOCF imputation.  
  
Selective reporting (reporting bias)  
Unclear risk  All relevant outcomes were reported.  
Other bias  Unclear risk  N/A  
  
8. Pauer 2011  
Methods  14-week multicentre, randomised, double-blind, placebo-controlled trial  
  
  
Participants  
Fibromyalgia according to ACR classification. Pain ≥ 40/100 mm and pain diary score ≥ 4 
on 11-point numerical rating scale in week before randomisation N = 747  
Mean age 49 years, 91% female, 76% white  
Baseline mean pain score: 6.7/10  
  
Interventions  
1-week placebo run-in phase, 2-week randomised dose escalation phase, 12-week fixed-dose 
phase  
Placebo, n = 184  
Pregabalin 300 mg, n = 184  
Pregabalin 450 mg, n = 182  
Pregabalin 600 mg, n = 186  
  
  
Outcomes  
Pain: Daily diary mean pain (NRS 0-10); 30%/50% reductions in pain intensity 
Fatigue: MAF (NRS 1-50)  
Sleep: MOS Sleep Problems Index (NRS 0-100)  
Depression: HADS (NRS 0-21)  
Anxiety: HADS (NRS 0-21)  
Health Related Quality of Life: SF-36 (NRS 50-0)  
Patient-perceived improvement: PGIC (1-7)  
AEs: Observed or spontaneously reported AEs; laboratory results, physical examinations, ECG  
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Notes  Pfizer sponsored. LOCF used to account for missing data and participant withdrawal.   
  
Risk of bias table  
Bias  Authors Judgement  Support for judgement  
Random sequence generation (selection 
bias)  
Unclear risk  Stated to be randomised however the method of 
sequence generation is not described.  
Allocation concealment (selection bias)  Unclear risk  Not described.  
Blinding of participants and personnel 
(performance bias  
Unclear risk  Double-Blind - no further details of methods used  
Blinding of outcome assessment (detection 
bias)  
Unclear risk  Double-Blind - no further details of methods used  
  
Incomplete outcome data (attrition bias)  
Unclear risk  LOCF imputation.  
  
Selective reporting (reporting bias)  
Low risk  All relevant outcomes were reported.  
Other bias  Unclear risk  Size - 50 to 199 participants were selected per 
treatment arm (182 to 186)  
  
      
Characteristics of excluded studies  
Arnold 2007  
Reason for exclusion  Pooled analysis using results from a previous study by [Crofford 
et al, 2005]  
  
Arnold 2012  
Reason for exclusion  Pooled analysis of three open-label extension studies  
  
  
Arnold 2014b  
 
Reason for exclusion  Participants selected were already receiving anti-depressant 
medication  
  
Arnold 2014c  
 
Reason for exclusion  Participants selected were already receiving anti-depressant 
medication  
  
Arnold 2015  
 
Reason for exclusion  Duration of the study was less than 8 weeks.  
  
Arnold 2016  
 
Reason for exclusion  Participants selected were under the age of 18 years.   
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Byon 2010  
 
Reason for exclusion  Summary report of 4 randomised controlled trials  
  
Emir 2010  
 
Reason for exclusion  Summary report of 4 randomised controlled trials  
  
Häuser 2009  
 
Reason for exclusion  Summary report of 5 randomised controlled trials  
  
Moore 2007  
 
Reason for exclusion  Summary report of 5 randomised controlled trials  
  
NCT00760474 2012    
 
Reason for exclusion  Duration of the study was less than 8 weeks.  
NCT01268631 2010    
Reason for exclusion  Cross-over study (2x2 weeks)  
  
NCT01904097 2013    
 
Reason for exclusion  Not double-blind  
  
Ohta 2013  
 
Reason for exclusion  Non-randomised; open-label extension trial  
  
Ramzy 2016  
 
Reason for exclusion  Participants were co-administered anti-depressant medication  
  
Roth 2012  
 
Reason for exclusion  Duration of the study was less than 8 weeks  
  
Russel 2009  
 
Reason for exclusion  Summary report of 2 randomised controlled trials  
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Characteristics of ongoing studies  
NCT02146430  
Study name  A randomized, double-blind, placebo- and active-controlled study of 
DS-5565 for treatment of pain associated with fibromyalgia  
Methods  13-week randomised, parallel, double-blind, placebo- and active 
controlled study  
Participants  ≈1294 Participants  
Clinical diagnosis using the American College of Rheumatology 
(ACR) classification criteria; pain intensity ≥ 40/100 Men and women 
over 18 years  
Interventions  DS-5565 (mirogabalin) 15 mg tablet, once daily  
DS-5565 (mirogabalin) 15 mg tablet, twice daily  
Pregabalin 150 mg capsule, twice daily  
Placebo tablet matching DS-5565 tablet  
Placebo capsule matching pregabalin capsule  
Participants take half daily dose in first week  
Outcomes  ≥ 30% and ≥ 50% responders at 13 weeks  
PGIC  
Fibromyalgia symptoms  
Adverse events  
Withdrawals  
Starting date  May 2014  
Contact information  Daiichi Sankyo Inc, Domenico Merante, MD  
Notes  Estimated completion date: March 2017  
  
 
References 
References to studies included in this review  
Arnold, LM., Russell, IJ., Diri, EW., Duan, WR., Young, JP., Sharma, U., Martin, SA., 
Barrett, JA., and Haig, G. [2008] A 14-week, randomized, double-blinded, placebo-
controlled monotherapy trial of pregabalin in patients with fibromyalgia. Pain; 
9(9):792-805.  [DOI: 10.1016/j.jpain.2008.03.013]  
Arnold, LM., Arsenault, P., Huffman, C., Patrick, JL., Messig, M., Chew, ML., Sanin, 
L., Scavone, JM., Pauer, L., and Clair, AG. [2014] Once daily controlled-release 
pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, 
randomized withdrawal, placebo controlled study. Current Medical Research and 
Opinion; 30(10):2069-2083. [DOI:  
10.1185/03007995.2014.928275]  
Crofford, LJ., Rowbotham, MC., Mease, PJ., Russell, IJ., Dworkin, RH., Pregabalin 
1008105 Study Group, et al. [2005] Pregabalin for the treatment of fibromyalgia 
syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis 
and Rheumatism; 52(4):1264-73. [DOI: 10.1002/art.20983]  
The Plymouth Student Scientist, 2018, 11 (1), 39 - 93 
85	 
	 
Crofford, LJ., Mease, PJ., Simpson, SL., Young, JP., Martin, SA., Haig, GM., et al. 
[2008] Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief 
(FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain; 
136(3):419-31. [DOI: 10.1016/j.pain.2008.02.027]  
Mease, PJ., Russell, IJ., Arnold, LM., Florian, H., Young, JP., Martin, SA., et al. 
[2008]   
A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the 
treatment of patients with fibromyalgia. Journal of Rheumatology; 35 (3):502-14. 
[PMID: 18278830]  
Nasser, K., Kivitz, AJ., Maricic, MJ., Silver, DS., Silverman, SL. [2014] Twice daily 
versus once nightly dosing of pregabalin for fibromyalgia: a double-blind randomized 
clinical trial of efficacy and safety. Arthritis Care and Research; 66(2):293-300. [DOI:  
10.1002/acr.22111]  
Ohta, H., Oka, H., Usui, C., Ohkura, M., Suzuki, M., Nishioka, K. [2012] A 
randomized, doubleblind, multicenter, placebo-controlled phase III trial to evaluate 
the efficacy and safety of pregabalin in Japanese patients with fibromyalgia. Arthritis 
Research and Therapy; 14(5):217. [DOI: 10.1186/ar4056]  
Pauer, L., Winkelmann, A., Arsenault, P., Jespersen, A., Whelan, L., Atkinson, G. An 
international, randomized, double-blind, placebo-controlled, phase III trial of 
pregabalin monotherapy in treatment of patients with fibromyalgia. Journal of 
Rheumatology; 38(12):2643-52. [DOI: 10.3899/jrheum.110569]  
 
References to studies excluded from this review  
Arnold, LM., Crofford, LJ., Martin, SA., Young, JP., Sharma, U. [2007] The Effect of 
Anxiety and Depression on Improvements in Pain in a Randomized, Controlled Trial 
of Pregabalin for Treatment of Fibromyalgia. Pain Medicine; 8(8):633-638. 
[DOI:10.1111/j.15264637.2007.00332.x]		
 
Arnold, LM., Emir, B., Murphy, KT., Zeiher, BG., Pauer, L., Scott, G., Petersel, D. 
[2012] Safety Profile and Tolerability of Up to 1 Year of Pregabalin Treatment in 3 
Open-Label Extension Studies in Patients With Fibromyalgia. Clinical Therapeutics; 
34(5):1092-1102. [DOI: doi: 10.1016/j.clinthera.2012.03.003]  
Arnold, L., Sarzi-Puttini, P., Arsenault, P., Khan, TS., Brown, PB., Clair, A., Driscoll, 
J., Landen, J., Pauer, L. [2014b] Pregabalin improves fibromyalgia symptoms in 
patients with fibromyalgia and comorbid depression receiving antidepressant 
medication: results from a randomized, 2-way crossover, double-blind, placebo-
controlled study. Pain; 15(4):74. [DOI: 10.1016/j.jpain.2014.01.306]  
The Plymouth Student Scientist, 2018, 11 (1), 39 - 93 
86	 
	 
Arnold, L., Sarzi-Puttini, P., Asenault, P., Khan, T., Brown, PB., Clair, A., Driscoll, J., 
Landen, J., Pauer, L. [2014c] Pregabalin is effective irrespective of antidepressant 
class in fibromyalgia patients currently receiving antidepressant medication for 
comorbid depression. Pain; 15(4):75. [DOI: 
http://dx.doi.org/10.1016/j.jpain.2014.01.307]  
Arnold, LM., Sarzi-Puttini, P., Arsenault, P., Khan, T., Bhadra-Brown, P., Clair, A.  
[2015] Efficacy and safety of pregabalin in patients with fibromyalgia and comorbid 
depression taking concurrent antidepressant medication: a randomized, placebo-
controlled study. Journal of Rheumatology; 42(7):1237-44. [DOI: 
10.3899/jrheum.141196]  
The Plymouth Student Scientist, 2018, 11 (1), 39 - 93 
 
87	 
	 
Arnold, LM., Schikler, KN., Bateman, L., Khan, T., Pauer, L., Bhadra-Brown, P., 
Clair, A., Chew, ML., Scavone, J. [2016] Safety and efficacy of pregabalin in 
adolescents with fibromyalgia: a randomized, double-blind, placebo-controlled trial 
and a 6-month open-label extension study. Pediatric Rheumatology; 14(46). [DOI: 
10.1186/s12969-016-0106-4]  
Byon, W., Ouellet, D., Chew, M., Ito, K., Burger, P., Pauer, L. [2010] Exposure-
response analyses of the effects of pregabalin in patients with fibromyalgia using 
daily pain scores and patient global impression of change. Journal of Clinical 
Pharmacology; 50(7):803-15. [DOI:  
10.1177/0091270009352187]  
Emir, B., Murphy, TK., Petersel, DL., Whalen, E. [2010] Treatment response to 
pregabalin in fibromyalgia pain: effect of patient baseline characteristics. Expert 
Opinion on  
Pharmacotherapy; 11(14):2275-80. [DOI: 10.1517/14656566.2010.509717]  
Häuser, W., Bernardy, K., Uçeyler, N., Sommer, C. [2009] Treatment of fibromyalgia 
syndrome with gabapentin and pregabalin--a meta-analysis of randomized controlled 
trials. Pain; 145(1):69-81. [DOI: 10.1016/j.pain.2009.05.014]  
Moore, RA., Straube, S., Wiffen, PG., Derry, S., McQuay HJ. [2009] Pregabalin for 
acute and chronic pain in adults. Cochrane Database of Systematic Reviews; 8(3). 
[DOI:  
10.1002/14651858.CD007076.pub2]  
Pfizer (NCT00760474) [2012]. A double-blind, placebo-controlled cross-over study in 
fibromyalgia subjects to examine effects of pregabalin on brain response to 
mechanical pain as assessed by functional magnetic resonance imaging, proton 
magnetic resonance spectroscopy and subjective ratings. [Other: 
clinicaltrials.gov/ct2/show/NCT00760474]  
Pfizer (NCT01268631) [2010]. Mechanism-based choice of therapy: can treatments 
success in fibromyalgia patients be coupled to psychophysical pain modulation 
profile? [Other: clinicaltrials.gov/ct2/show/NCT01268631]  
Pfizer (NCT01904097) [2013]. Study of the brain with optic functional neuroimaging 
in patients with chronic pain using transcranial direct current stimulation. [Other: 
clinicaltrials.gov/ct2/show/NCT01904097]  
 
Ohta, H., Oka, H., Usui, C., Ohkura, M., Suzuki, M., Nishioka, K. [2013] An open-
label long-term phase III extension trial to evaluate the safety and efficacy of 
pregabalin in Japanese patients with fibromyalgia. Modern Rheumatology; 
23(6):1108-15. [DOI:  
10.1007/s10165-012-0803-x]  
The Plymouth Student Scientist, 2018, 11 (1), 39 - 93 
 
88	 
	 
Ramzy, EA. [2016] Comparative efficacy of newer antidepressants in combination 
with pregabalin for fibromyalgia syndrome: a controlled, randomized study. Pain 
Practice; 17(1); 32-40. [DOI: 10.1111/papr.12409]  
 
Roth, T., Lankford, DA., Bhadra, P., Whalen, E., Resnick, EM. [2012] Effect of 
pregabalin on sleep in patients with fibromyalgia and sleep maintenance 
disturbance: a randomized, placebo controlled, 2-way crossover polysomnography 
study. Arthritis Care and Research; 64(4):597-606. [DOI: 10.1002/acr.21595]  
Russell, IJ., Crofford, LJ., Leon, T., Cappelleri, JC., Bushmakin, AG., Whalen, E. 
[2009] The effects of pregabalin on sleep disturbance symptoms among individuals 
with fibromyalgia syndrome. Sleep Medicine; 10(6): 604-10. [DOI: 
10.1016/j.sleep.2009.01.009]  
References to ongoing studies  
NCT02146430 [2012]. A randomized, double-blind, placebo- and active-controlled 
study of DS5565 for treatment of pain associated with fibromyalgia.  
clinicaltrials.gov/ct2/show/NCT02146430 (accessed 23 November 2016). [4388205; 
Sponsor ID: DS5565-A-E309]   
  
Additional references  
Arnold, LM., Emir, B., Murphy, TK., Zeiher, BG., Pauer, L., Scott, G., and Petersel, 
D. [2012] Safety Profile and Tolerability of Up to 1 Year of Pregabalin Treatment in 3 
Open-Label Extension Studies in Patients With Fibromyalgia. Clinical Therapeutics; 
34(5); 1092-1102. [DOI: http://dx.doi.org/10.1016/j.clinthera.2012.03.003]  
Bellato, E., Marini, Eleonora., Castoldi, F., Barbasetti, N., Mattei, L., Bonasia, DE., 
and Blonnda, D. [2012] Fibromyalgia Syndrome: Etiology, Pathogenesis, Diagnosis 
and Treatment. Pain Research and Treatment. [DOI: 10.1155/2012/426130]  
Bennett, R., Jones, J., Turk, D., Russell, I. and Matallana, L. [2007] An internet 
survey of 2,596 people with fibromyalgia. BMC Musculoskeletal Disorders; 8(2). 
[DOI: 10.1186/14712474-8-27]  
Bhusal, S., Diomampo, S., and Magrey, MN. [2016] Clinical utility, safety and efficacy 
of pregabalin in the treatment of fibromyalgia. Drug Healthcare and Patient Safety; 8; 
13-23. [DOI:  
10.2147/DHPS.S95535]  
Branco, JC., Bannwarth, B., Failde, I., Abello Carbonell, J., Blotman, F., Spaeth, M., 
Saraiva, F., Nacci, F., Thomas, E., Caubère, JP., Le Lay, K., Taieb, C., and Matucci-
Cerinic M. [2010]  
Prevalence of Fibromyalgia: a survey in five European countries. Seminars in 
Arthritis and Rheumatism; 39(6); 448-453. [DOI: 10.1016/j.semarthrit.2008.12.003]  
The Plymouth Student Scientist, 2018, 11 (1), 39 - 93 
 
89	 
	 
Clauw, D. [2014] Fibromyalgia: a clinical review. JAMA; 311(15), 1547-1555. [DOI  
10.1001/jama.2014.3266]  
Cohen, J. (2013). Statistical Power Analysis for the Behavioral Sciences. 1st ed. 
Hoboken: Taylor and Francis.  
Cook, R. and Sackett, D. [1995] The number needed to treat: a clinically useful 
measure of treatment effect. BMJ, 310(6977), pp.452-454.  
Dechartres, A., Trinquart, L., Boutron, I. and Ravaud, P. [2013] Influence of trial 
sample size on treatment effect estimates: meta-epidemiological study. BMJ; 
346f2304. [DOI:	https://doi.org/10.1136/bmj.f2304]  
Derry, S., Cording, M., Wiffen, PJ., Law, S., Phillips, T., and Moore, RA. [2016] 
Pregabalin for pain in fibromyalgia adults. Cochrane Database of Systematic 
Reviews; 9; [DOI: 10.1002/14651858.CD011790.pub2]  
 
Dworkinl, RH., Turk, DC., Wyrwich, KW., Beaton, D., Cleeland, CS., Farrar, JT.,  
Haythornthwaite, JA., Jensen, MP., Kerns, RD., Ader, DN., Brandenburg, N., Burke, 
LB., Cella, D., Chandler, J., Cowan, P., Dimitrova, R., Dionne, R., Hertz, S., Jadad, 
AR., Katz, NP., Kehlet, H., Kramer, LD., Manning, DC., McCormick, C., McDermott, 
MP., McQuay, HJ., Patel, S., Porter, L., Quessy, S., Rappaport, BA., Rauschkolb, C., 
Revicki, DA., Rothman, M., Schmader, KE., Stacey, BR., Stauffer, JW., von Stein, T., 
White, RE., Witter, J., Zavisic, S. [2008] Interpreting the clinical importance of 
treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Pain; 
9(2); 105-121. [DOI: 10.1016/j.jpain.2007.09.005]  
 
Gahr, M., Freudenmann, R., Hiemke, C., Kölle, M. and Schönfeldt-Lecuona, C. 
[2013] Pregabalin abuse and dependence in Germany: results from a database 
query. European Journal of Clinical Pharmacology; 69(6), 1335-1342. [DOI: 
10.1007/s00228-012-1464-6]  
Häuser, W., Henningsen, F. [2014] Fibromyalgia syndrome: a somatoform disorder? 
European Journal of Pain; 18(8), 1052-1059. [DOI: 10.1002/j.1532-
2149.2014.00453.x]  
Häuser, W., Ablin, J., Fizcharles, MA., Littlejohn, G., Usui, C. and Walitt, B. [2015] 
Fibromyalgia. Nature Reviews: Disease Primers; 1; 15022. [DOI: 
10.1038/nrdp.2015.22]  
Higgins, JPT., Thompson, SG., Deeks, JJ., Altman, DG. [2003] Measuring 
Inconsistency in metaanalyses. BMJ; 327(7414); 557-560. 
[DOI:10.1136/bmj.327.7414.557]  
Jadad, AR., Moore, RA., Carroll, D., Jenkinson, C., Reynolds, DJ., Gavaghan, DJ., 
and McQuay, HJ. [1996] Assessing the quality of reports of randomised clinical trials: 
is blinding necessary? Controlled Clinical Trials; 17(1); 1-12. [PMID: 8721797]  
The Plymouth Student Scientist, 2018, 11 (1), 39 - 93 
 
90	 
	 
Jahan, F., Nanji, K., Qidwai, W., and Quasim, R. [2012] Fibromyalgia Syndrome: An 
Overview of Pathophysiology, Diagnosis and Management. Oman Medical Journal; 
27(3); 192-195. [DOI: 10.5001/omj.2012.44]  
 
Kashikar-Zuck, S., Cunningham, N., Soumitri., S., Bromberg, MH., Lynch-Jordan, 
AM.,  
Strotman, D., Peugh, J., Noll, J., Ting, TV., Powers, SW., Lovell, DJ., and Arnold, 
LM. [2014] LongTerm Outcomes of Adolescents With Juvenile-Onset Fibromyalgia in 
Early Adulthood. Pediatrics; 133(3); 592-600. [DOI: 10.1542/peds.2013-2220].   
Koroschetz, J., Rehm, SE., Gockel, U., Brosz, M., Freynhagen, R., Tölle, TR., and 
Baron, R. [2011] Fibromyalgia and neuropathic pain – differences and similarities. A 
comparison of 3057 patients with diabetic painful neuropathy and fibromyalgia. BMC 
Neurology; 11(55). [DOI: 10.1186/1471-2377-11-55]  
 
Lange, M., Petermann, F. [2010] influence of depression of fibromyalgia: a 
systematic review. Pain; 24:326-33. [DOI: 10.1007/s00482-010-0937-8]  
 
Leresche, L. [2011] Defining gender disparities in pain management. Clinical 
Orthopaedics and Related Research; 469(7); 1871-1877. [DOI: 10.1007/s11999-
010-1759-9]  
 
Lunn, MP., Hughes, RA., and Wiffen, PJ. [2014] Duloxetine for treating painful 
neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic 
Reviews; (1): CD007115. [DOI: 10.1002/14651858.CD007115.pub3]  
 
Mease, P., Arnold, LM., Choy, EH., Clauw, DJ., Crofford, L., Glass, JM., Martin, SA., 
Morea, J., Simon, L., Strand, V., and Williams, DA. [2009] Fibromyalgia Syndrome 
Module at OMERACT 9. Journal of Rheumatology; 36(10); 2318-2329. [DOI: 
10.3899/jrheum.090367]  
 
Moore, RA., Straube, S., Paine, J., Phillips, CJ., Derry, S., and McQuay, HJ. [2010] 
Fibromyalgia: Moderate and substantial pain intensity reduction predicts 
improvement in other outcomes and substantial quality of life gain. Pain; 149(2); 360-
364. [DOI:  
10.1016/j.pain.2010.02.039]  
Moore, RA., Eccleston, C., Derry, S., Wifen, P., Bell, RF, Straube, S., McQuay, H., 
[2010b]  
ACTINPAIN Writing Group of the IASP Special Interest Group on Systematic 
Reviews in  
Pain Relief; Cochrane Pain and Palliative and Supportive Care Systematic Review 
Group Editors. Pain; 150(3); 386-389. [DOI: 10.1016/j.pain.2010.05.011]  
Moore, A., Derry, S., Eccleston, C., and Kalso, E. [2013] Expect analgesic failure; 
pursue analgesic success. BMJ; 346:f2690. [DOI: 10.1136/bmj.f2690]  
The Plymouth Student Scientist, 2018, 11 (1), 39 - 93 
 
91	 
	 
Moore, RA., Derry, S., Aldington, D., Cole, P., Wiffen, PJ. [2015] Amitriptyline for 
neuropathic pain in adults. Cochrane Database of Systematic Reviews; (7): 
CD008242. [DOI:  
10.1002/14651858.CD008242.pub3]  
 
O’Brien, EM., Staud, RM., Hassinger, AD., McCulloch, RC., Craggs, JG., Atchison, 
JW., Price, DD., and Robinson, ME. [2010] Patient-centered perspective on 
treatment outcomes in chronic pain. Pain Medicine; 11(1); 6-15. [DOI: 
10.1111/j.1526-4637.2009.00685.x]  
 
Ohta, H., Oka, H., Usui, C., Ohkura, M., Suzuki, M., and Nishioka, K. [2013] An 
open-label long-term phase III extension trial to evaluate the safety and efficacy of 
pregabalin in Japanese patients with fibromyalgia. Modern Rheumatology/the Japan 
Rheumatism Association; 23(6):1108-15. [DOI: 10.1007/s10165-012-0803-x]  
 
Okifuki, A., and Hare, BD. [2013] Management of Fibromyalgia Syndrome: Review of 
Evidence. Pain and Therapy; 2(2); 87-104. [DOI: 10.1007/s40122-013-0016-9]  
 
Queiroz, LP. [2013] Worldwide Epidemiology of Fibromyalgia. Current Pain and 
Headache Reports; 17(8); 356. [DOI: 10.1007/s11916-013-0356-5]  
 
Rahman, A., [2014] Underwood, M. and Carnes, D. Fibromyalgia. BMJ; 24(348), 
1224. [DOI:  
10.1136/bmj.g1224].  
Review Manager (RevMan) [2014]  [Computer program]. Version 5.3. Copenhagen: 
The Nordic Cochrane Centre, The Cochrane Collaboration.  
Ross, RL., Jones, KD., Bennett, RM., Ward, RL., Druker, BJ., and Wood, LJ. [2010] 
Preliminary Evidence of Increased Pain and Elevated Cytokines in Fibromyalgia 
Patients with Defective Growth Hormone Response to Exercise. The Open 
Immunology Journal; 3; 9-18. [PMID: 20467575]  
 
Sawilowsky, SS. [2009] New effect size rules of thumb. Journal of Modern Applied 
Statistical Methods; 8(2), 597-599.  
 
Sommer C, Häuser W, Burgmer M, Engelhardt R, Gerhold K, Petzke F, et al. [2012] 
Etiology and pathophysiology of fibromyalgia syndrome. Pain; 26:259-67. [DOI: 
10.1007/s00482012-1174
The Plymouth Student Scientist, 2018, 11 (1), 39 - 93 
 
92	 
	 
Straube, S., Derry, S., Moore, RA., and McQuay HJ. [2010] Pregabalin in fibromyalgia: 
metaanalysis of efficacy and safety from company clinical trial reports. Rheumatology; 
49(4); 706-715. DOI: 10.1093/rheumatology/kep432  
Taylor, CP., Angelotti, T., and Fauman, E. [2007] Pharmacology and mechanism of action 
of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for 
antiepileptic drug discovery. Epilepsy Research; 73(2); 137-150. [DOI:  
10.1016/j.eplepsyres.2006.09.008]  
Toth, C. [2014] Pregabalin: latest safety evidence and clinical implications for the 
management of neuropathic pain. Therapeutic Advances in Drug Safety; 5(1); 38-56. [DOI:  
10.1177/2042098613505614]  
Tzellos, TG., Toulis, KA., Goulis, DG., Papazisis, G., Zampeli, VA., Vakfari, A., and 
Kouvelas, D. [2010] Gabapentin and pregabalin in the treatment of fibromyalgia: a 
systematic review and meta-analysis. Journal of Clinical Pharmacy and Therapeutics; 
35(6); 639-656. [DOI: 10.1111/j.1365-2710.2009.01144.x]  
Üçeyler, N., Sommer, C., Walitt, B., Häuser W. [2013] Anticonvulsants for fibromyalgia. 
Cochrane Database of Systematic Reviews; (10):CD010782. [DOI:  
10.1002/14651858.CD010782]  
Vincent, A., Lahr, BD., Wolfe, F., Clauw, DJ., Whipple, MO., Oh, TH., Barton, DL., and St  
Sauver, J. [2013] Prevalence of fibromyalgia: a population-based study in Olmsted County,  
Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care and Research; 
65(5); 786-792. [DOI: doi: 10.1002/acr.21896]  
Wallace, DJ., Gavin, IM., Karpenko, O., Barkhordar, F., and Gillis, BS. [2015] Cytokine and 
chemokine profiles in fibromyalgia rheumatoid arthritis and systemic lupus erythematosus: a 
potentially useful tool in differential diagnosis. Rheumatology International; 35(6); 991-996. 
[DOI: 10.1007/s00296-014-3172-2]   
Wiffen, PJ., Derry, S., Moore, RA., Aldington, D., Cole, P., Rice, A., Lunn, M., Hamunen, K., 
Haanpaa, M., and Kalso, EA. [2013] Antiepileptic drugs for neuropathic pain and 
fibromyalgia – an overview of Cochrane reviews. Cochrane Database of Systematic 
Reviews; (11):CD010567. [DOI: 10.1002/14651858.CD010567.pub2]  
 
Wolfe, F., Smythe, HA., Yunus, MB., Bennett, RM., Bombardier, C., Goldenberg, DL.,  
Tugwell, P., Campbell, SM., Ableles, M. and Clark, P. [1990] The American College of  
Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter 
Criteria Committee. Arthritis and Rheumatism; 33(2); 160-162. PMID: 2306288  
 
Wolfe, F., Clauw, DJ., Fitzcharles, MA., Goldenberg, DL., Katz, RS., Mease, P., Russell, 
AS., Russell, IJ., Winfield, JB., and Yunus, MB. [2010] The American College of 
Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom 
severity. Arthritis Care and Research; 62(5); 600-110. [DOI: 10.1002/acr.20140.]  
 
 
 
The Plymouth Student Scientist, 2018, 11 (1), 39 - 93 
 
93	 
	 
Wolfe, F., Clauw, DJ., Fitzcharles, MA., Goldenberg, DL., Häuser, W., Mease, P., Russell, 
AS., Russell, IJ., and Winfield, JB. [2011] Fibromyalgia criteria and severity scales for 
clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic 
Criteria for Fibromyalgia. The Journal of Rheumatology; 38(6); 1113-1122. [DOI:  
10.3899/jrheum.100594]  
Wolfe, F.,  Brähler, E., Hinz, A., and Häuser, W. [2013] Fibromyalgia prevalence, somatic 
symptom reporting, and the Dimensionality of Polysymptomatic distress: Results from a 
survey of the general population. Arthritis Care & Research; 65(5), 777-785. [DOI:  
10.1002/acr.21931]  
Woolf, CJ. [2011] Central sensitization: implications for the diagnosis and treatment of pain. 
Pain; 152(3); 2-15. [DOI: 10.1016/j.pain.2010.09.030]  
Yunus, MB. [2008] Central sensitivity syndromes: a new paradigm and group nosology for 
fibromyalgia and overlapping condition, and the related issue of disease versus illness.  
Seminars in Arthritis and Rheumatology; 37(6), 339-352. [DOI:  
10.1016/j.semarthrit.2007.09.003]  
  
  
